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Abstract 
 
Efforts to precisely identify tumor human leukocyte antigen (HLA) bound peptides capable of 
mediating T cell-based tumor rejection still face important challenges. Recent studies suggest 
that non-canonical tumor-specific HLA peptides that derive from annotated non-coding regions 
could elicit anti-tumor immune responses. However, sensitive and accurate mass-
spectrometry (MS)-based proteogenomics approaches are required to robustly identify these 
non-canonical peptides. We present an MS-based analytical approach that characterizes the 
non-canonical tumor HLA peptide repertoire, by incorporating whole exome sequencing, bulk 
and single cell transcriptomics, ribosome profiling, and a combination of two MS/MS search 
tools. This approach results in the accurate identification of hundreds of shared and tumor-
specific non-canonical HLA peptides and of an immunogenic peptide from a downstream 
reading frame in the melanoma stem cell marker gene ABCB5. It holds great promise for the 
discovery of novel cancer antigens for cancer immunotherapy.
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Introduction 
The efficacy of T cell-based cancer immunotherapy relies on the recognition of HLA-bound 
peptides (HLAp) presented on the surface of cancer cells. Characterizing and classifying 
immunogenic epitopes is an ongoing endeavor for developing cancer vaccines and adoptive 
T cell-based immunotherapies. Neoantigens, which are peptides derived from mutated 
proteins, are absolutely tumor-specific yet mostly patient-specific and are implicated in the 
therapeutic efficacy of checkpoint blockade immunotherapy1-4. In contrast to tumor-specific 
neoantigens, tumor-associated antigens that are shared across patients may be more 
attractive for immunotherapy due to the more efficient and rapid treatment of a greater number 
of patients 5-7. Recent studies have focused on the discovery of non-canonical antigens, which 
are antigens derived from the translation of presumed non-coding transcripts. Such aberrant 
translation leads to the generation of peptide sequences that are missing in conventional 
protein sequence repositories and are therefore considered novel8,9. If such translation events 
lead to the presentation of novel and immunogenic HLA ligands, then these occurrences could 
substantially expand the repertoire of targetable epitopes for cancer immunotherapy9-20.  
Currently, approximately 1% of the entire genome is annotated as protein-coding regions, yet, 
75% of the genome can be transcribed and theoretically translated, potentially offering a pool 
of novel peptide targets21.   
To date, the only analytical methodology allowing the direct identification of the in vivo 
presented HLAp repertoire is mass spectrometry (MS)22. Often, MS-based immunopeptidomic 
discoveries are limited to the standard, available protein sequence database, usually 
containing only annotated protein-coding sequences. Recently, several studies have included 
protein sequences derived from the translation of transcripts identified from RNA-Seq, or from 
ribosome profiling, into MS-based searches9,23-28. Overall, these studies warrant further 
development in many key aspects: Importantly, elevated false discovery rates (FDRs) for the 
non-canonical space can occur when MS reference data are populated with protein sequences 
derived from all potential three- or six-frame translations of transcribed regions29. Several 
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studies did not compute FDRs or applied sample-specific thresholds for FDR calculations24,28. 
Furthermore, rigorous experimental confirmation with targeted MS for such non-canonical 
sequences is currently lacking. Also, current workflows often introduce a risk of bias by pre-
filtering peptide identifications based on HLA-binding predictions24,28. Finally, the overall 
biogenesis of non-canonical HLA binding peptides (noncHLAp) remains understudied due to 
a-priori restriction of the search space to tumor-specific non-canonical protein sequences24.  
Here we describe a proteogenomic approach to identify tumor-specific noncHLAp derived 
from translation of presumed non-coding transcripts, such as from (long) non-coding genes 
(lncRNAs), pseudogenes, untranslated regions (UTRs) of coding genes, and transposable 
elements (TEs). We performed immunopeptidomics and integrated in our analyses tumor 
exome, bulk and single cell transcriptome, and whole translatome data. We then implemented 
NewAnce, a new analytical approach for non-canonical element identification that combines 
two MS/MS search tools, along with group-specific FDR calculations to identify noncHLAp. 
Together, this unveiled an unprecedentedly large number of novel noncHLAp, highlighting the 
potential of this approach to enlarge the range of targetable epitopes in cancer 
immunotherapy.  
Results 
A comprehensive strategy for noncHLAp identification 
MS-based immunopeptidomics was performed on seven patient-derived melanoma cell lines 
and two pairs of lung cancer samples with matched normal tissues (Fig. 1a). This resulted in 
the identification of 60,320 unique protein-coding HLA class I bound peptides (protHLAIp) and 
11,256 protein-coding HLA class II-bound peptides (protHLAIIp). For the exploration and 
validation of in vivo naturally presented non-canonical peptides, whole exome and RNA-Seq 
data were generated for all samples (Fig. 1a and Supplementary Table 1). For every sample, 
we extracted from RNA-Seq data expressed non-canonical genes such as lncRNAs and 
pseudogenes. In addition, we applied an analytical pipeline to assign TE-derived RNA-Seq 
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reads to single loci (See Methods section for more details), resulting in expression data for 
transcribed TEs. All the above transcripts were subsequently translated in three forward open 
reading frames (ORFs) (stop-to-stop). For every sample, the novel in-silico translated protein 
sequences were concatenated to a personalized canonical proteome reference containing 
allelic variant information from patient tumor exome data. Finally, we searched the MS 
immunopeptidomics data against these personalized reference databases. 
Database size affects the level of false positives in noncHLAp identifications  
In silico translation of transcripts in three reading frames results in a large number of potential 
protein sequences. In proteogenomics, searching MS data against such inflated protein 
reference databases may propagate false positives 29,30. Hence, our first investigative step 
was to understand the impact of database size on the level of false positives in 
immunopeptidomics datasets. We searched reference databases containing canonical (i.e. 
UniProt) and our non-canonical protein sequences with a single search tool (MaxQuant) and 
a global 1% FDR. The accuracy was assessed by assigning HLA-binding prediction scores to 
the MS-identified HLAIp with MixMHCpred31. We reasoned that non-canonical HLA class I 
bound peptides (noncHLAIp) should follow the same binding rules as protHLAIp32. First, we 
compared a generic non-canonical protein sequence database derived from the three forward 
frame (“three-frame”) translation of all annotated non-coding genes from GENCODE33 with a 
sample-specific protein sequence database derived from the three-frame translation of 
lncRNAs and pseudogenes from the RNA-Seq data, using an expression cut –off value of 
FPKM (fragments per kilobase of transcript per million mapped reads >0). Additional 
databases of decreasing size were assembled, by retaining only those sequences that 
originated from more highly expressed genes (FPKM >2, >5 or >10). Reducing the size of the 
database by personalizing and focusing on highly expressed genes led to an increase in the 
percentage of noncHLAIp that were predicted to bind to their respective HLA alleles 
(MixMHCpred p-value<0.05) (Fig. 1b).  
NewAnce improves accurate identification of hundreds of noncHLAp  
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Restricting the database to protein sequences originating from highly expressed genes should 
on one hand improve the accuracy of MS based non-canonical peptide identification, while on 
the other hand lead to the potential loss of peptides coming from lower expressed transcripts. 
To circumvent the need to exclude protein sequences based on low expressed transcripts, we 
developed the computational module called NewAnce, which combines the MS search tools 
MaxQuant34 and Comet35, with the implementation of a group-specific strategy for FDR 
calculation. All HLAp identified by either of the search tools were consequently matched 
against an up-to-date UniProt sequence database (95,106 protein sequences, with isoforms) 
to extract novel noncHLAp that do not map back to known human proteins in UniProt. For 
every sample, FDRs were calculated separately for the protHLAp and noncHLAp (Fig. 1c and 
Supplementary Fig. 1a). Only consensus (intersection) peptide-spectrum-matches (PSMs) 
from Comet and MaxQuant were retained for further downstream analyses. As most false 
positive PSMs are specific to one search tool, NewAnce led to an estimated FDR of <0.001%.  
With NewAnce, the number of protHLAIp identified across 11 samples ranged from 3,490 to 
16,672 per sample, and from 817 to 5,777 for protHLAIIp (Supplementary Table 2). 
Furthermore, up to 148 noncHLAIp per individual sample were identified with NewAnce, with 
a combined total of 452 unique noncHLAIp (Supplementary Table 2 and Supplementary 
Data 1). Over the four HLA-II expressing samples investigated, only 4 lncRNA derived 
noncHLAIIp out of 11,256 protHLAIIp were detected. 
We employed two complementary methods to assess the accuracy of our approach. First, we 
predicted the binding of peptides to their respective HLA allotypes. Across all 11 samples, 
90% of the noncHLAIp and 91% of the protHLAIp identified with NewAnce were predicted to 
bind the HLA allotypes (median values, Supplementary Fig. 1b). As expected, NewAnce 
detected less HLAp than Comet (PSM FDR of 3%) or MaxQuant (PSM FDR of 3%) and more 
HLAp when the routinely applied FDR of 1% was applied by MaxQuant alone (Fig. 1d, 
Supplementary Fig. 1b-f and Supplementary Table 2). Importantly, for the noncHLAIp 
repertoire (lncRNAs, pseudogenes and TEs), significantly higher percentages of peptides 
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predicted to bind the HLA allotypes were identified by NewAnce compared with those identified 
by MaxQuant or Comet alone (Fig. 1e and Supplementary Fig. 1b-f).   
In addition, we correlated the observed mean retention time (RT) of a given peptide against 
the predicted hydrophobicity index (HI), which corresponds to the percentage of acetonitrile at 
which the peptide elutes from the analytical HPLC system. Predicting the sequence specific 
hydrophobicity indices of peptides identified by NewAnce showed that the RT distribution of 
non-canonical peptides was on the diagonal line, and was not significantly different than the 
distribution of protein-coding peptides, supporting their correct identification (Fig. 1f) (one 
sided F-test p-value:1.0e+0). However, we observed a significant difference in RT distribution 
when comparing non-canonical peptides from NewAnce to those identified by MaxQuant (one 
sided F-test p-value: 6.3e−32) or Comet alone (one sided F-test p-value: 8.4e−20) (Fig. 1g).  
Moreover, a commonly applied approach to boost non-canonical peptide identifications would 
be to search the MS data with a single tool (or a union of two tools) applying a permissive FDR 
followed by an additional step of filtering to include only peptides predicted to bind the relevant 
HLA allotypes36. To evaluate this approach, we compared the correlation between HI and RT 
of predicted non-canonical HLA binders and non-binders identified at 3% PSM FDR with either 
MaxQuant (Fig. 1h) or Comet (Fig. 1i). Predicted binders showed better correlations between 
HI and RT compared to non-binders (one sided F-test p-values 8.4e-6 for MaxQuant and 4.4e-
18 for Comet). These correlations where fairly poor for MaxQuant, while a much better 
correlation was calculated for Comet likely due to the conservative group specific FDR control 
strategy we applied for Comet. In conclusion, these comprehensive analyses underline the 
superiority of NewAnce over the above alternatives.  
Notably, when examining the source protein sequence origin of all noncHLAIp, we detected 
an enrichment towards the C-terminus of their precursor protein sequences. This effect was 
also observed for protHLAIp originating from similarly short canonical proteins 
(Supplementary Fig. 2a-b).  
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MS-targeted validation and Ribo-Seq confirm a fraction of noncHLAIp 
To experimentally validate the NewAnce computational pipeline, we investigated a selection 
of NewAnce-identified HLAp from a melanoma sample (0D5P) with targeted MS-based 
analyses. All identified noncHLAIp (lncRNAs and TEs, n=93), as well as a similar-sized subset 
of protHLAIp from clinically relevant tumor-associated antigens (TAAs, n=71) detected in 
0D5P were synthesized in their heavy isotope-labelled forms for MS-targeted validation. The 
selected TAAs were chosen solely based on their interesting tumor-associated biological 
functions, as these are known cancer/testis or melanoma antigens. Here, MS-based targeted 
confirmation with parallel reaction monitoring (PRM) was directly compared between the non-
canonical and canonical peptide groups by spiking the heavy-labelled peptides into multiple 
independent replicates of 0D5P immunopeptidomic samples. This revealed that confirmation 
is superior for protHLAIp than for noncHLAIp (78.5% for TAAs versus 55.2% for lncRNAs and 
27.7% for TEs) (Fig. 2a, Supplementary Table 3 and Supplementary Data 2). We also 
observed that PRM validation is dependent on source RNA expression level (Supplementary 
Fig. 3a-d), measured peptide intensities (Supplementary Fig. 3e-h), and detectability by 
MS/MS across multiple 0D5P replicates (Supplementary Fig. 3i-l).  
As a further targeted validation strategy for the noncHLAIp, Ribo-Seq, which involves the 
sequencing of ribosome protected fragments (RPFs), was performed on the sample 0D5P. 
Periodic RPF distributions (see Methods section) that supported translation in the correct ORF 
of transcript encoding the identified noncHLAIp was observed for 22.2% of TE peptides and 
21.3% of lncRNA peptides, compared to 100% of the TAAs (Fig. 2b). Notably, nine lncRNA 
HLAIp, and two TE peptides were validated by both PRM and by Ribo-Seq approaches. For 
example, the noncHLAIp SYLRRHLDF was confirmed by MS (Fig. 2c), and the translated 
ORF that generated the peptide was mapped back to two novel transcripts (Fig. 2d-e).  
Low RNA expression level is a limiting step in noncHLAIp presentation 
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We then characterized in more depth the expression levels of source RNAs encoding the 
HLAIp. For this purpose, we compared all identified source genes of protHLAIp to source 
genes of noncHLAIp in the 0D5P sample. The protein-coding source genes had a median 
FPKM value of 9.3, whereas the non-canonical source genes showed overall lower 
expression, with a median FPKM of 2.1 (Fig. 3a-b). Generally, the number of unique peptides 
identified per gene increased with higher levels of expression. PRM-validated noncHLAIp 
covered a large and dynamic range of gene expression, and interestingly, a few were 
confirmed at very low source RNA expression levels (Fig. 3c-d).  
The lower levels of expression of source genes that generated noncHLAp prompted us to 
investigate the regulation of non-canonical HLA presentation, and whether this can be induced 
with drug treatments. We treated melanoma cells either with decitabine, a DNA 
methyltransferase inhibitor, known to reactivate epigenetically silenced genes, or with IFN 
gamma (IFNγ), known to upregulate antigen presentation37-40. As expected, when T1185B 
melanoma cells were treated with IFNγ, we observed large quantitative changes in the 
presentation of protHLAIp. Specifically, enhanced presentation of peptides derived from 
immune-related genes was observed, likely due to their higher gene expression and the 
increase in the production of HLA-I molecules (Supplementary Fig. 3m). However, no 
obvious change was observed for the noncHLAIp repertoire, with 60% of the identified 
noncHLAIp remaining unaltered upon IFNγ treatment, suggesting that transcription is the 
limiting step in presentation of noncHLAIp (Supplementary Fig. 3n). Furthermore, we 
explored the effect of hypomethylating agent decitabine on noncHLAIp in melanoma. Although 
decitabine induced expression of selected hypomethylating-induced immune genes41, TAAs 
and non-canonical transcripts (Supplementary Fig. 3o-q), changes in the 0D5P noncHLAIp 
repertoire were modest (data not shown). Nonetheless, we identified and confirmed the 
presence of a unique decitabine -induced noncHLAIp derived from a lncRNA (Supplementary 
Fig. 3r).  
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Integration of Ribo-Seq data improves the coverage of immunopeptidomes and 
identification of additional noncHLAIp  
Next, we hypothesized that immunopeptidomes would be better associated with translatomes 
than transcriptomes. To build the translatome-based database for MS search, all ORFs 
showing periodic RPF distribution were extracted for the 0D5P sample and the transcribed 
frames were translated in-silico. This technique reduced the size of the search space, and we 
used this independent discovery method in our study in order to identify additional noncHLAIp, 
including those from novel ORF in coding genes. 
We investigated to what extent a protein sequence database inferred by Ribo-Seq could 
replace the search performed with protein sequences derived from three-frame translation of 
expressed RNA species. Using 0D5P as a representative immunopeptidomic dataset, we 
observed a positive correlation between RNA expression and HLAIp sampling (see Methods 
section) searched against a canonical protein sequence database (r= 0.392) (Fig. 3e). Then 
we searched the same immunopeptidomics MS data against the de novo assembled Ribo-
Seq inferred database, and we correlated this HLAIp sampling with RNA abundance (Fig. 3f) 
or with translation rates based on the spectral coefficient of 3-periodic signal in Ribo-Seq data 
(see Methods section) (Fig. 3g). This resulted in a significantly higher positive correlation 
between HLAIp sampling searched against a Ribo-Seq inferred database and translation rate 
(r=0.574) than with the overall RNA abundance (r=0.431, two-sided p-value<10e-16). Thus, 
there is evidence that the immunopeptidome, at least for 0D5P sample, is better captured by 
the translatome than the transcriptome. 
Notably, restricting the database to actual translation products by Ribo-Seq provided a deeper 
coverage of the immunopeptidome than a canonical protein sequence database (Fig. 3h). 
This led to the identification of additional noncHLAIp derived from ORFs originating in 5’ or 3’ 
untranslated regions, presumed non-coding RNAs, retained introns, and pseudogenes, with 
the majority coming from either annotated upstream or entirely novel ORFs (Fig. 3i-j). Many 
of these additional noncHLAIp were missed using the RNA-Seq inferred database.  Of note, 
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this method also takes into account products arising from ribosomal frameshifting, which could 
be relevant in the context of non-canonical antigens42. Interestingly, only 16 common lncRNA-
derived noncHLAIp were found when comparing both strategies. This likely reflects the limited 
detection of periodic Ribo-Seq reads in transcripts with low expression, or low mappability 
(Supplementary Fig. 4a).  
Single-cell transcriptomics reveals transcriptional heterogeneity of presumed non-
coding genes 
Tumor cell heterogeneity could present one of the key factors for immune escape leading to 
the inefficacy of cancer immunotherapies. In an attempt to understand the pattern of non-
coding gene expression at the single cell level, we performed single-cell RNA-Seq (scRNA-
Seq) on the 0D5P melanoma cell line. Overall, 1,400 cells were sequenced at a total depth of 
176 million reads resulting in the detection of a median of 6,261 genes per cell (total of 19,178 
detected genes). As expected, clustering of 0D5P cells revealed dependency on the cell cycle 
status (Fig. 4a) and source genes associated with cell cycle could be explored (Fig. 4b-c). 
First, we confirmed that the antigen presentation machinery was uniformly expressed in all 
cells, as well as many of the selected TAAs (Fig. 4d). 
Out of the 71 non-canonical source genes identified by bulk transcriptomics, 35 were detected 
also at the single-cell level (Fig. 4d). HLAIp derived from non-canonical source genes were 
detected with higher coverage at the single cell were those confirmed by PRM (6 out of 8 
genes confirmed in >50% cells, and 14 out of 27 genes in <50% cells) and by Ribo-Seq (37 
out of 41 genes confirmed in >50% cells, and 25 out of 46 genes in <50% cells) (Fig. 4d, 
Supplementary Fig. 4b-c). Profiles of source non-canonical genes clearly show expression 
heterogeneity and nearly none of them were uniformly expressed across cells, though the 
limited sensitivity of scRNA-Seq could account for this variation. Expression of LINC00520 
was higher than expected given its detection in only 75% of cells, suggesting that it is not 
uniformly expressed (Fig. 4d).  
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We further explored marker genes associated with a cluster of 0D5P cells significantly 
expressing LINC00520 (Fig. 4e-f). Interestingly, we found that LINC00520 was co-expressed 
with the ATP-binding cassette sub-family B member 5 (ABCB5) gene, that mediates 
chemotherapeutic drug resistance in stem-like tumor cell subpopulations in human malignant 
melanoma and is commonly over-expressed on circulating melanoma tumor cells43, with beta-
catenin (CTNNB1) which is a key regulator of melanoma cell growth44, and with its critical 
downstream target the microphthalmia-associated transcription factor (MITF) that mediates 
melanocytes differentiation45 (Fig. 4g). The source RNA expression of ABCB5 was detected 
in only 37% of 0D5P cells, however, as shown below, the ABCB5 gene encodes a novel ORF 
that gives rise to an immunogenic epitope. Indeed, immune-targeting of non-canonical targets 
expressed on a subset of aggressive or melanoma stem cells could be beneficial.   
Identification of tumor-specific noncHLAIp 
As our initial MS search space was not restricted to protein sequences derived from tumor-
specific transcripts, we investigated in retrospect the potential of identified noncHLAIp to be 
classified as tumor specific. A public database of RNA sequencing data from 30 different 
healthy tissues (GTEx46) was assessed at a strict 90th percentile, which represents the 
expression value cut-off for the top 10% expressed genes. We identified 335 noncHLAIp from 
280 lncRNA genes in the seven melanoma samples of which 23% were expressed only in our 
tumor samples, and not in any of the healthy tissues (excluding testis due to its immune-
privileged nature) (Fig. 5a). Among these was the tumor-specific LINC00518 gene that has 
been proposed as a two-gene classifier for melanoma detection together with the tumor 
associated antigen PRAME47.  
 
Using an in-house curated inventory of human transposable element (TE)-derived protein 
sequences (from three-frame translations) as reference, we found 88 unique TE-HLAIp in our 
whole dataset. Some were derived from autonomous TEs, such as long tandem repeat (LTR) 
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retrotransposons and long interspersed nuclear elements (LINEs), and others from non-
autonomous retrotransposons such as short interspersed nuclear elements (SINE) or SINE-
VNTR-Alu (SVA) elements (Supplementary Fig. 5a). Importantly, 60 of the 88 TE-HLAIp were 
found in presumed non-coding TE regions and therefore represent completely novel HLA 
peptides. These TE-HLAIp would have been overlooked in canonical MS-based searches. 
Furthermore, 10% of the noncHLAIp derived from TEs were retrospectively shown to be 
expressed only in a single healthy tissue, excluding testis. For example, peptides derived from 
AluSq2 SINE/Alu and L1PA16 LINE/L1 elements were expressed only in skin and testis. 
Finally, selected TAAs were also investigated in the same manner for melanoma and lung 
tissue samples separately (Supplementary Fig. 5b-c).  
We next examined whether our approach could identify tumor specific non-canonical targets 
in the ideal case where normal and tumor biopsies are available, i.e. from the two lung cancer 
patients included in the present dataset. For example, out of 14,120 non-canonical genes 
expressed in patient C3N-02289, we found that 409 were exclusively expressed at the RNA 
level in the patient’s tumor. We identified 45 noncHLAIp in patient C3N-02289 (Fig. 5b), out 
of which 10 peptides were identified only in the tumor tissue by MS (Fig. 5c). Four of these 
source genes were tumor-specific when compared to the matched healthy tissue of patient 
C3N-02289 (90th percentile Transcripts per Million (TPM) ≤ 1). However, when compared to 
the GTEx database, only one noncHLAIp from RP11-566H8.3 was finally considered as tumor 
and testis- specific for patient C3N-02289 (Fig. 5c). The same analyses with TE genes 
resulted in the identification of 1,159 elements that were expressed at the RNA level only in 
the C3N-02289 tumor. Of those, we identified the LTR7B LTR/ERV1 TE HLAIp that was 
presented in the tumor tissue, however this gene is also expressed in healthy brain. In 
comparison, we were able to identify six tumor-associated protHLAIp, which were only found 
in the tumor tissue (BIRC5, TERT, FAP, SPAG4, MAGEA9 and BCL2L1). 
NoncHLAIp are shared across patient samples 
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We investigated the likelihood of shared noncHLAIp amongst the nine tumor samples 
analyzed and identified 27 peptides that were detected in at least two patient samples. Seven 
noncHLAIp, already validated in 0D5P, were confirmed by PRM in at least one other patient 
sample that expressed HLA allotypes with identical or highly similar binding specificities 
(Supplementary Table 4), with a total of 15 individually detected PRM events (Fig. 6a). 
Interestingly, one noncHLAIp VTDQASHIY, derived from microcephalin-1 antisense RNA 
(MCPH1-AS1), was confirmed independently with PRM in three melanoma or lung cancer 
patients (Supplementary Fig. 6a-b). Further, the shared presentation of noncHLAIp 
AAFDRAVHF, derived from the family of LINEs (LINE/L2) on chromosome 6, was confirmed 
in two melanoma samples (Supplementary Fig. 6c-d). Interestingly, the corresponding 
source RNA expression is skin- and testis-restricted. 
Next, we interrogated a large collection of immunopeptidomic datasets (ipMSDB48, 137 
biological cancer tissue/cell line sources, 39 biological healthy tissues/cell line sources; 2,250 
MS raw files in total) and obtained the first large-scale signature of noncHLAIp presentation. 
In total, 398,622 peptides were obtained for the healthy samples in ipMSDB, versus 488,500 
peptides for cancer samples. We observed that 92 out of the 96 tumor-specific noncHLAIp 
(90th percentile TPM ≤ 1 in maximum 3 tissues) identified in this present study were re-
identified in ipMSDB (Fig. 6b), 52 of those were detected in at least one additional sample in 
ipMSDB excluding our investigated samples. Another 72 additional novel noncHLAIp were 
discovered from the same tumor specific non-canonical source genes. Remarkably, we 
observed that noncHLAIp presentation was significantly enriched in tumor samples in ipMSDB 
(cancer versus healthy p-value=0.048, melanoma versus healthy p-value=0.025), and more 
significantly when B and T cells, which were rapidly expanded in culture or EBV-transformed, 
were excluded from the analysis (p-value = 0.009) (Fig. 6c). Interestingly, two noncHLAIp from 
HAGLROS (KVLAGTVLFK and VLAGTVLFK), identified in the lung cancer tissue only, were 
exclusively found only in cancer samples in ipMSDB, mainly in ovarian cancer samples, where 
genetic association with HAGLROS was previously reported49.   
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Assessing immunogenicity of noncHLAIp with autologous T cells  
The involvement of the noncHLAIp in tumor immune recognition was assessed by measuring 
IFNγ release by autologous tumor-infiltrating lymphocytes (TILs) or peripheral blood 
mononuclear cells (PBMCs) upon peptide stimulation. Out of the 786 peptides screened (94 
TEs, 421 lncRNAs, 56 alternative ORFs, 215 TAAs), we confirmed the specific recognition of 
autologous TILs to TAAs HYYVSMDAL and RLPSSADVEF from tyrosinase (TYR), and 
RYNADISTF from tyrosinase-related protein 1 (TYRP1) in melanoma sample 0D5P, and TAA 
YLEPGPVTA from PMEL in melanoma sample T1015A. One non-canonical peptide 
KYKDRTNILF, derived from the downstream ORF (dORF) of the melanoma stem cell marker 
ABCB5 gene in 0D5P, was found to be  immunogenic in both CD8+ TILs and CD8+ T cells 
from peripheral blood lymphocytes (PBLs) (Fig. 6d-e). Notably, this peptide is shared across 
three additional melanoma samples in ipMSDB.  
Discussion 
Our proteogenomics approach led to the stringent identification of hundreds of noncHLAIp 
derived from non-coding genes, TEs and alternative ORFs. This was achieved with NewAnce, 
a novel computational module which overcame the challenge of reduced sensitivity and 
specificity when searching against large MS search spaces29,50. NewAnce is publically 
available and can be used with any (non-canonical) protein sequence databases of interest. 
We rigorously tested the validity of noncHLAIp identifications with HLA binding predictions, 
sequence-specific retention characteristics, targeted MS analyses, and provided evidence of 
translation in peptide-encoding ORFs by Ribo-Seq. We confirmed with these multiple 
strategies that NewAnce is superior to MaxQuant and Comet alone, across all investigated 
samples. As an example with one patient, we conducted PRM and Ribo-Seq analyses to 
compare a subset of protHLAIp to non-canonical antigen classes (lncRNAs and TEs), thereby 
validating at the experimental level a recurrently identified noncHLAIp. We found that 
noncHLAIp had an overall lower confirmation rate than protHLAIp, possibly due to their lower 
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expression, which also led to their stochastic detection by MS. Interestingly, the expression 
and translation of microproteins derived from presumed non-coding RNAs in the heart were 
recently discovered using a Ribo-Seq directed proteogenomics approach, with  evidence of 
translation in the correct ORF confirmed for 22.5% of the lncRNAs and 55.4% of the 
micropeptides validated by PRM MS51. Importantly, our results additionally demonstrate that 
the correct identification of noncHLAIp in proteogenomic workflows requires proper FDR 
controls and validation using multiple independent methods.  
 
Combining immunopeptidomics with RNA-Seq and Ribo-Seq datasets enables the 
comprehensive assessment of how transcription, translation and HLA presentation are 
correlated. Despite the different methodological challenges52-54, the expected correlations 
were observed between HLA presentation level and expression based on both RNA-Seq and, 
more clearly on Ribo-Seq, perhaps because translation is biologically closer to antigen 
processing and presentation. In addition, we found that in melanoma 0D5P, most of the novel 
noncHLAIp derived from the Ribo-Seq inferred database originated from source genes 
harboring upstream ORFs (uORFs). Of note, uORFs can trigger non-sense-mediated decay 
of mRNAs and provide a rich source of noncHLAIp55-57.   
 
While a previous study has shown that the presentation of non-canonical peptides is enhanced 
by inflammatory stimuli, only the presentation of specific HLA peptides were documented58. In 
contrast, our large-scale analyses of both decitabine and IFNγ-treated cells did not detect 
profound changes in noncHLAIp presentation, although non-canonical source genes were 
induced. Hence, we hypothesize that low copy number of such noncHLAIp still remains a 
limiting factor for their presentation. Moreover, corroborating prior research28, we report the 
enrichment of noncHLAIp originating from the C-termini of source protein sequences. 
Translation products of such presumed non-coding regions could be considered as defective 
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ribosomal products that are expected to be unstable and rapidly degraded, likely bypassing 
the proteasome59.   
 
Given the lack of comprehensive healthy tissue immunopeptidomics libraries from patients, 
we propose a workflow to retrospectively filter for tumor-specific noncHLAIp with publicly 
available RNA-Seq databases (such as GTEx46). We further validated our proteogenomics 
approach in the ideal situation where both tumor and matched normal tissue are available. 
Two overlapping epitopes were identified in lncRNA HAGLROs, which were expressed and 
presented only in the lung tumor tissue. This lncRNA has been implicated in cancer 
progression60,61 and should now be prioritized for downstream validation. Moreover, while 
Laumont et al.24 first proposed the existence of shared noncHLAIp, our work validates that 
noncHLAIp can be shared across multiple tumor samples and thus we anticipate greater 
efficiency in treatment with such shared noncHLAIp compared to private neoantigens62,63. 
 
Expression of tumor-specific noncHLAp in a subpopulation of tumor cells suggests a 
dependency on a molecular or functional state. For example, the immunogenic noncHLAIp, 
derived from dORF in the ABCB5 gene was moderately expressed in only 37% of the 
melanoma cells, compared to the immunogenic TYR and TYRP1, both of which were highly 
and uniformly expressed. Although targets for immunotherapy should ideally be uniformly 
presented in all cancer cells in order to minimize outgrowth of escaping cells, immune pressure 
on selected tumor cell subsets of particular biological relevance – such as cancer stem-like 
cells, tumor cells with epithelial-mesenchymal transition features or proliferating tumor cells – 
could affect tumor behavior and be clinically beneficial. Ideally, such targets would also be 
upregulated by inflammatory cytokines or pharmacologically.  
 
Indeed, we found such immunogenic noncHLAIp from 0D5P derived from the dORF of the 
ABCB5 gene. ABCB5 has been shown to be expressed in malignant-melanoma-initiating cells 
and was suggested to be responsible both for the progression and chemotherapeutic 
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refractoriness of advanced malignant melanoma43. Through an IL1β/IL8/CXCR1 cytokine 
signaling circuit, it has been shown to control IL1β secretion and maintain slow cycling and 
chemoresistance64. Blockage of ABCB5 reversed resistance to multiple chemotherapeutic 
agents, induced cellular differentiation, and impaired tumor growth in vivo64. We found that 
ABCB5 was differentially co-expressed in a cluster of 0D5P cells with the transcription factor 
MITF and beta-catenin, and others that  their expression may be enriched in melanoma stem 
cell populations65. The presence of spontaneous specific T cells recognizing the noncHLAIp 
derived from the dORF of the ABCB5 gene, in both peripheral blood and TILs, suggests no 
central tolerance, and that this target could allow immune-targeting of melanoma stem cell 
subpopulation to drastically affect tumor growth.    
 
Out of 571 noncHLAIp screened, immune recognition by rapidly expanded TILs and PBMCs 
was detected for only a single immunogenic noncHLAIp. Various mechanisms could account 
for this lack of recognition. First, we were only able to screen autologous TILs that had been 
long propagated in culture. We have previously reported that TIL ex vivo expansion may lead 
to depletion of T cell clones that recognize tumor neoantigens66. Second, it is possible that the 
melanoma cells, which had to be expanded considerably in culture for immunopeptidomics 
analyses, could have altered their HLA peptide repertoire, leading to the identification of 
noncHLAIp that were originally not present in freshly extracted cells. However, we also 
interrogated snap-frozen lung cancer tissues and still could not detect immune recognition of 
identified non-canonical targets in autologous PBMCs. Alternatively, the ability of noncHLAIp 
to induce a natural immune response might be inferior to protHLAp. Low expression might 
limit uptake by professional antigen presenting cells and hence priming of  naïve T cells in vivo 
through cross presentation. Similarly, engagement of CD4+ T helper cells through HLA class 
II presentation might be limited as well. Nevertheless, tumor-specific non-canonical targets 
may still be valuable for cancer vaccines, even when no prior immune response against the 
targets has been detected ex vivo, as previously shown for neoantigens4,67,68. More research 
should be performed to thoroughly assess the ability of noncHLAp to augment protective 
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immune response in vivo. Such approaches are supported by evidence in mouse models that 
peptides derived from non-canonical regions can be spontaneously recognized and leveraged 
in cancer immunotherapy24,69.    
Remarkably, across tumor types, the potential number of predicted noncHLAp is orders of 
magnitude larger than that of neoantigens encompassing non-synonymous somatic 
mutations. As T cell-based screenings currently have limited throughput and are expensive70, 
an accurate and cost-effective non-canonical target discovery pipeline is crucial for their 
further development and use in cancer immunotherapy. With the renewed interest in cancer 
vaccines and the constantly growing number of antigens screened for immune recognition, we 
expect that enough training data will become available to allow the development of accurate 
predictors of immunogenicity. Combining this with our newly developed module NewAnce to 
shortlist in vivo presented noncHLAp and to rank them according to their predicted 
immunogenicity, will facilitate the comprehensive exploration of non-canonical antigens, their 
association with immune responses and their potential for building effective cancer 
immunotherapies.   
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Methods  
Patient material 
Melanoma cell lines (0D5P, 0MM745, 0NVC) were generated as follows: Patient-derived 
tumors were cut into small pieces before being transferred into a digestion buffer containing 
collagenase type I (Sigma Aldrich) and DNase I (Roche) for at least one hour. Dissociated 
cells were washed and maintained in RPMI 1640 + GlutaMAX medium (Life Technologies) 
supplemented with 10% heat-inactivated FBS (Dominique Dutscher) and 1% 
Penicillin/Streptomycin Solution (BioConcept). If fibroblasts appeared, they were selectively 
eliminated with G418 (Geneticin; Gibco) treatment. The primary melanoma cell lines T1185B, 
T1015A, Me290 and Me275 were generated at the Ludwig Cancer Research Center, 
Department of Oncology, University of Lausanne, as previously described71,72. All established 
melanoma cells were subsequently grown to 1 x 108 cells, collected by centrifugation at 151 x 
g for 5 min, washed twice with ice cold PBS and stored as dry cell pellets at -20°C until use. 
For the in vitro 72h treatment with IFNγ (100 IU/mL, Miltenyl Biotec), T1185B cells were grown 
to 2 x 108 in triplicates. For the treatment with Decitabine (DAC, Sigma-Aldrich), 2 x 108 
melanoma cells were grown for 8 days in 0.5 µM Decitabine with medium and drug renewal 
on the 4th day.  
 
Autologous TILs were expanded from fresh melanoma tumor samples corresponding to 
patients 0D5P, 0MM745, 0NVC, LAU1185 (tumor cell line T1185B), LAU1015 (tumor cell line 
T1015A), LAU203 (tumor cell line Me290) and LAU50 (tumor cell line Me275) at the Ludwig 
Cancer Research Center, Department of Oncology, University of Lausanne. The fresh tissues 
were manually cut into fragments of one to two mm3. The tumour fragments were then placed 
in 24-well plates containing RPMI CTS grade (Life Technologies), 10% Human serum 
(Biowest), 0.025 M HEPES (Life Technologies), 55 μmol/L 2- Mercaptoethanol (Life 
Technologies) and supplemented with IL-2 (6,000 IU/mL, Proleukin) for three to five weeks. 
Following this pre-REP (Rapid Expansion Protocol), TILs were then expanded with another 
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REP as follows: 5x106 TILs were stimulated with irradiated feeder cells (Ratio 1:200), anti-
CD3 (OKT3, 30 ng/mL, Miltenyl biotec) and IL-2 (3,000 IU/mL) for 14 days.  After 14 days of 
REP, about 2x109 TILs were harvested, washed and cryopreserved until use. The purity (i.e. 
the % of CD3 T cells) was >95%. As additional control, one flask with the exact same REP 
conditions without TILs was cultured in parallel and no cells were detectable at day 14. REP 
TILs were thawed in 5 IU/mL DNAse I (Sigma-Aldrich) and cultured in 3000 IU/mL IL-2 for two 
days in RPMI 1640 Medium with GlutaMAX™ Supplement (Gibco), with the addition of 8% 
Human serum (Biowest), 10 mM  HEPES (Gibco), 50 μM Beta- Mercaptoethanol (Gibco), 100 
μM non-essential amino acids (Gibco), 100 IU/mL Penicillin and 0.1 mg/mL Streptomycin, 
2mM L-Glutamine (Gibco), 0.1 mg/mL Kanamycinsulfate (Carl Roth) and 1mM sodium 
pyruvate (Gibco).  Cells were then washed twice in complete medium and subsequently rested 
overnight in the presence of 150 IU/mL IL-2 prior to peptide stimulation.  
Snap-frozen normal and lung tumor tissue material from C3N-02289 (Lung squamous cell 
carcinoma, grade 2) and C3N-02671 (Lung adenocarcinoma, G2) were kindly provided by the 
International Institute of Molecular Oncology. Informed consent of the participants was 
obtained following requirements of the institutional review board (Ethics Commission, CHUV, 
Bioethics Committee, Poznan University of Medical Sciences, Poznań, Poland).  
All cells were tested negative for mycoplasma contamination. High resolution 4-digit HLA-I 
and HLA-II typing (Supplementary Table 1) was performed either at the Laboratory of 
Diagnostics, Service of Immunology and Allergy, CHUV, Lausanne or in-house with the 
following method: The amplification of the HLA was conducted with the TruSight HLA v2 
Sequencing Panel kit (CareDx) according to the manufacturer’s protocol. Sequencing was 
performed on the Illumina® MiniSeq™ System (Illumina) using paired-end 2x150 bp protocol. 
The data was analyzed with the Assign TruSight HLA v2.1 software (CareDx). 
 
Immunoaffinity purification of HLA peptides 
We performed HLA immunoaffinity purification following our previously established 
protocols39,73.  Briefly, W6/32 and HB145 monoclonal antibodies were purified from the 
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supernatant of HB95 (ATCC® HB-95™) and HB145 cells (ATCC® HB-145™) using protein-
A sepharose 4B (Pro-A) beads (Invitrogen), and antibodies were then cross-linked to Pro-A 
beads. Cell lysis was performed with PBS containing 0.25% sodium deoxycholate (Sigma-
Aldrich), 0.2 mM iodoacetamide (Sigma-Aldrich), 1 mM EDTA, 1:200 Protease Inhibitors 
Cocktail (Sigma-Aldrich), 1 mM Phenylmethylsulfonylfluoride (Roche), 1% octyl-beta-D 
glucopyranoside (Sigma-Alrich) at 4°C for 1 hour.  Lysates were cleared by centrifugation in a 
table-top centrifuge (Eppendorf) at 4°C at  21,191 x g for 50 min. Snap-frozen tissue samples 
were homogenized on ice in 3-5 short intervals of 5 seconds each using an Ultra Turrax 
homogenizer (IKA) at maximum speed. Lysates were cleared by centrifugation at 25,000 rpm 
in a high speed centrifuge (Beckman Coulter, JSS15314) at 4°C for 50 minutes. We employed 
the Waters Positive Pressure-96 Processor (Waters) and 96-well single-use micro-plates with 
3µm glass fiber and 10µm polypropylene membranes (Seahorse Bioscience, ref no: 360063). 
Anti-pan HLA-I and HLA-II antibodies cross-linked to beads were loaded on their respective 
plates. For tissue samples, a depletion step of endogenous antibodies was required containing 
Pro-A beads. The lysates were passed sequentially through HLA-I and -II plates at 4°C. Plates 
were then washed separately with varying concentrations of salts using the processor. Finally, 
beads were washed twice with 2 mL of 20 mM Tris-HCl pH 8. 
Sep-Pak tC18 100 mg Sorbent 96-well plates (Waters, ref no: 186002321) were used for the 
purification and concentration of HLA-I and HLA-II peptides. Plates were conditioned and 
direct elution of the HLA complexes and the bound peptides from the affinity plate with 1% 
trifluoroacetic acid (TFA; Sigma-Aldrich) was performed. After washing the C18 wells with 2 
mL of 0.1 % TFA, HLA-I peptides were eluted with 28% Acetonitrile (ACN; Sigma-Aldrich) in 
0.1% TFA. HLA-II peptides were eluted from the class II C18 plate with 500 µL of 32% ACN 
in 0.1% TFA. Recovered HLA-I and -II peptides were dried using vacuum centrifugation 
(Concentrator plus, Eppendorf) and stored at -20°C.  
 
LC-MS/MS analyses 
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The LC-MS/MS system consists of an Easy-nLC 1200 (Thermo Fisher Scientific) hyphenated 
with a Q Exactive HF-X mass spectrometer (Thermo Fisher Scientific). Peptides were 
separated on a 450 mm analytical column of 75 µm inner diameter.  
For HLAIp, we used the following gradient for analytical separation, with a flow rate of 250 
nL/min using a mix of 0.1 % FA (solvent A) and 0.1% FA in 80 % ACN (solvent B): 0–5 min 
(5% B); 5-85 min (5-35% B); 85-100 min (35-60 % B); 100-105 min (60-95% B); 105-110 min 
(95% B); 110-115 min (95-2% B) and 115-125 min (2% B).  For HLAIIp, the gradient was run 
as follows: 0-5 min (2-5% B); 5-65 min (5-30% B); 65-70 min (30-60% B); 70-75 min (60-95 % 
B); 75-80 min (95% B), 80-85 min (95-2% B) and 85-90 min (2% B). 
 
The mass spectrometer was operated as follows for discovery data-dependent acquisition 
(DDA). Full MS spectra were acquired in the Orbitrap from m/z = 300-1650 with a resolution 
of 60’000 (m/z = 200) and ion accumulation time of 80 ms. The auto gain control (AGC) was 
set to 3e6 ions. MS/MS spectra were acquired in a data-dependent manner on 10 most 
abundant precursor ions (if present) with a resolution of 15,000 (m/z = 200), ion accumulation 
time of 120 ms and an isolation window of 1.2 m/z. The AGC was set to 2e5 ions, dynamic 
exclusion to 20 s and a normalized collision energy (NCE) of 27 was used for fragmentation.  
No fragmentation was performed for HLAIp in case of assigned precursor ion charge states of 
four and above, and for HLAIIp, in case of assigned precursor ion charge states of one, and 
also from six and above. The peptide match option was disabled. 
Parallel Reaction Monitoring 
Selected endogenous HLAp that required confirmation by parallel reaction monitoring (PRM) 
were ordered as crude (PePotec grade 3) or HPLC grade (purity > 70%) with one stable 
isotope labelled amino acid from Thermo Fisher Scientific. The mass spectrometer was 
operated at a resolution of 120’000 (at m/z = 200) for MS1 full scan, scanning a mass range 
from 300-1650 m/z with an ion injection time of 100ms and an AGC of 3e6. Then each peptide 
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was isolated with an isolation window of 2.0 m/z prior to ion activation by HCD (NCE = 27). 
Targeted MS/MS spectra were acquired at a resolution of 30’000 (at m/z = 200) with an ion 
injection time of 60ms and an AGC of 5e5. Only those peptides that ultimately pass quality 
control were considered for further downstream analyses through spiking them back into the 
patient sample. 
The PRM data was processed and analyzed by Skyline (v4.1.0.18169, MacCoss Lab 
Software)74 and an ion mass tolerance of 0.02 m/z was used to extract fragment ion 
chromatograms. To display MS/MS spectra, raw data was converted into MGF by MSConvert 
(Proteowizard v3.0.18136) and peak lists for the heavy peptide and light counterpart were 
extracted. The assessment of MS/MS matching was performed by pLabel (Version 2.4.0.8, 
pFind studio, Sci. Ac.) and Skyline. 
 
Exome/RNA sequencing 
DNA was extracted for HLA typing and exome sequencing with the commercially available 
DNeasy Blood & Tissue Kit (Qiagen), following manufacturers’ protocols. For tissue samples, 
pelleted DNA was used, which was obtained after lysis of the tissue and centrifugation during 
HLA immunopurification. The supernatant was used for HLA immunopurification, whereas the 
pelleted DNA was homogenized with a pestle (70 mm, 1.5/2.0mL, Schuett-Biotec) before DNA 
extraction following manufacturer’s instructions.  
RNA extraction for RNA sequencing was achieved using the total RNA isolation RNeasy Mini 
Kit (Qiagen) following manufacturer’s protocols for all melanoma cell lines (including DNAse I 
(Qiagen) on-column digestion). Frozen pieces of tumor and normal tissue samples (<20 mg) 
were directly submerged in 350 µL of RLT buffer supplemented with 40 µM DTT (Sigma-
Aldrich). Tissues were then completely homogenized on ice using a pestle (70 mm, 1.5/2.0mL, 
Schuett-Biotec) and by passing the sample through a 26G needle syringe for five times (BD 
Microlance). Centrifugation was performed in a table-top centrifuge (Eppendorf) at 4°C at 
18,213 x g for 3 min, before the supernatant was removed and used for RNA extraction. All 
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subsequent steps are described in detail in the manufacturer’s protocol (including DNAse I 
(Qiagen) on-column digestion).  
Three micrograms of genomic DNA were fragmented to 200bp using a Covaris S2 (Covaris). 
Sequencing libraries were prepared with the Agilent SureSelectXT Reagent Kit (Agilent 
Technologies). Exome enrichment was performed with Agilent SureSelect XT Human All 
Exome v5 probes. Cluster generation was performed with the resulting libraries using the 
Illumina HiSeq PE Cluster Kit v4 reagents and sequenced on the Illumina HiSeq 2500 using 
SBS Kit v4 reagents. At least 70x coverage for the melanoma cell lines and PBMCs/TILs were 
required. For tumor/normal lung tissues, at least 100x coverage was required. Sequencing 
data were demultiplexed using the bcl2fastq Conversion Software (v. 1.84, Illumina). 
RNA quality was assessed on a Fragment Analyzer (Agilent Technologies) and all RNA had 
a RQN beween 7.4 and 10. RNA-seq libraries were prepared using 500 ng or 375 ng of total 
RNA with the Illumina TruSeq Stranded mRNA reagents (Illumina) following manufacturer’s 
recommendations. Libraries were quantified by a fluorimetric method and their quality 
assessed on a Fragment Analyzer (Agilent Technologies). Cluster generation was performed 
from the resulting libraries using the Illumina HiSeq PE Cluster Kit v4 reagents and sequenced 
on the Illumina HiSeq 2500 using HiSeq SBS Kit v4 paired end reagents for 2x100 cycles 
paired end sequencing. Sequencing data were de-multiplexed using the bcl2fastq2w 
Conversion Software (v. 2.20, Illumina). 
RNA-Seq data processing for lncRNA and gene expression analysis 
The GENCODE comprehensive gene annotation version 221,2 was downloaded from the 
GENCODE website (https://www.gencodegenes.org/releases/22.html). It was used to define 
the protein-coding and non-coding gene features including chromosome position, transcript 
structure, as well as transcript and protein sequences. Here, the human reference genome 
GRCh38/hg38 was downloaded from the UCSC Genome Browser website 
(http://hgdownload.cse.ucsc.edu/goldenPath/hg38/bigZips/) and was used as the genome 
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assembly. The RNA-seq reads were aligned to the GRCh38/hg38 reference genome using 
RNA-Star (v2.4.2a; https://github.com/alexdobin/STAR). The gene expression was 
normalized and calculated as in Fragments Per Kilobase of transcript per Million mapped 
reads (FPKM) values by Cufflinks (v2.2.1) (http://cole-trapnell-
lab.github.io/cufflinks/releases/v2.2.1/). The gene level RNA expression data of both protein-
coding and non-coding genes were used for downstream gene expression analysis33,75. 
RNA-Seq data processing for TE expression analysis 
Reads from the investigated samples and public data from GTEx were mapped to the human 
(GRCh37) genome using hisat2 v.2.1.076. Counts on genes and TEs were generated using 
featureCounts 1.6.277. To avoid read assignation ambiguity between genes and TEs, a gtf file 
containing both was provided to featureCounts. For repetitive sequences, an in-house curated 
version of the Repbase database was used (fragmented LTR and internal segments belonging 
to a single integrant were merged). Only uniquely mapped reads were used for counting on 
genes and TEs. Finally, features that did not have at least one sample with 20 reads were 
discarded from the analysis. Normalization for sequencing depth was done for both genes and 
TEs using the TMM method as implemented in the limma v.3.36.5 package of Bioconductor78 
and using the counts on genes as library size. 
Personalised sequence databases for non-coding genes 
The curated set of human ENCODE non-coding transcripts (GRCh37 reference assembly) 
was downloaded from https://www.gencodegenes.org/human/release_24lift37.html. Short 
ORFs (shORFs) in all three forward reading frames were identified using a stop-to-stop 
strategy. The minimum peptide length was set at 8 amino acids, and the longest polypeptide 
identified was 3644 amino acids. Unless otherwise mentioned, all non-coding genes that were 
expressed per sample (FPKM > 0) were translated in all three forward reading to build the 
personalized fasta file for non-coding genes.  
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Personalised sequence databases for protein-coding genes including variants 
GENCODE v24 (GRCh37 human reference assembly, downloaded from 
https://www.gencodegenes.org/human/release_24lift37.html) was chosen as the standard 
reference dataset. Whole exome sequence reads were aligned to the GRCh37 human 
assembly with BWA-MEM79 and variants were predicted using the GATK framework v3.7 and 
Picard Tools v 2.9.080. SNPs were defined as variants present in both tumor and germline, 
and somatic mutations (SNVs and indels) as present only in tumor. The GENCODE 
comprehensive gene annotation file, in GFF3 format, was parsed to extract genomic 
coordinate information for every exon in each protein coding transcript, and those coordinates 
were compared with sample-specific variant coordinates to derive non-synonymous amino 
acid changes within each protein. For every sample, we created a separate fasta file where 
residue mutation information was added to the header of the affected translated protein coding 
transcripts, in a format compatible with MaxQuant v1.5.9.4i as previously reported81.  
Mass Spectrometry Database Search  
We used two widely used search tools: Comet 2017.01 rev. 235 and the Andromeda search 
engine within MaxQuant v1.5.9.4i82. Both Andromeda and Comet allow searching for peptides 
with and without variants. Andromeda matched the MS/MS spectra of each sample against 
their personalized reference libraries (mentioned above). Similarly, the variants were 
annotated in the PEFF format (http://www.psidev.info/peff) for Comet. Both search tools were 
run with the same principal search parameters: precursor mass tolerance 20ppm, MS/MS 
fragment tolerance 0.02 Da, peptide length 8-15 for HLA-I only and 8-25 for HLA-I and HLA-II 
peptides and no fixed modifications. For samples 0D5P, 0VNC and OMM745, oxidation (M) 
and phosphorylation (STY) were set as variable modifications and for the remaining samples 
only Oxidation (M) was included as a variable modification. A PSM FDR of 3% was used for 
Andromeda as a first filter, and non-canonical reference sequences were loaded into the 
“proteogenomics fasta files” module for separate FDR calculations for protein-coding and non-
canonical sequences. 
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To assure that non-canonical peptide sequences do not match other protein coding genes, all 
peptides found by Andromeda or Comet were aligned against the UniProt (www.uniprot.org) 
sequence database (human reviewed sequences with isoforms, downloaded 18/12/2018), 
where leucine and iso-leucines were treated as equal since they are not distinguishable by 
mass spectrometry. If peptides were found matching standard UniProt sequences, they were 
assigned as protein-coding with the UniProt IDs. However, we assigned and kept TE peptide 
sequences that matched annotated TEs that were integrated into the human reference in 
UniProt.  
As schematically described in Supplementary Fig. 1a, the Comet FDR calculation was done 
separately for protein-coding and non-canonical PSMs with an in-house software written in 
Java, which utilizes the MzJava class library 83. All PSMs resulting from the Comet search, 
including the decoy PSMs (decoy hits originating from reversed sequences), were split into 
three sublists with PSMs of charge (Z) 1, 2, and charge 3 or higher. The three Comet scores 
XCorr, deltaCn and spScore were considered. It has been shown that when feature vectors 
are partitioned into different groups, group-wise local FDR (lFDR) calculation provides the 
most sensitive decision boundaries, for controlling the global FDR84. Therefore, the 3D space 
(XCorr, deltaCn and spScore) was partitioned into small cells (40 intervals in each dimension) 
and the lFDR was estimated for each cell. We used the following equation to calculate the 
lFDR: 
 (1) 
𝒍𝑭𝑫𝑹(𝒙, 𝒁) =
𝝅𝟎𝒑(𝒙|𝒁, 𝑯 = 𝟎)
𝝅𝟎𝒑(𝒙|𝒁, 𝑯 = 𝟎) + 𝝅𝟏𝒑(𝒙|𝒁, 𝑯 = 𝟏)
= (𝟏 +
𝝅𝟏
𝝅𝟎
∙
𝒑(𝒙|𝒁, 𝑯 = 𝟏)
𝒑(𝒙|𝒁, 𝑯 = 𝟎)
)
−𝟏
 
= (𝟏 +
𝝅𝟏
𝝅𝟎
𝜸(𝒙, 𝒁))
−𝟏
         
where 𝝅𝟎 and 𝝅𝟏 are the class probabilities for true (H=1) and wrong (H=0) PSMs, and  
𝒑(𝒙|𝒁, 𝑯 = 𝟎, 𝟏) are the probability distributions for feature vector  𝒙 =
(𝑿𝑪𝒐𝒓𝒓, 𝒅𝒆𝒍𝒕𝒂𝑪𝒏, 𝒔𝒑𝑺𝒄𝒐𝒓𝒆) of PSMs with charge Z. The probability ratio 𝜸(𝒙, 𝒁) is estimated 
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for every cell and charge using all the target and decoy PSMs. The 𝝅𝟏 𝝅𝟎⁄  ratios are calculated 
for the non-canonical and protein-coding groups separately and then the 𝝅𝟏 𝝅𝟎⁄  ratios are 
plugged into Equation (1). This way the lFDR values are calculated for every cell for both 
groups. For each cell i, the number of wrong hits (n0i) is set to the number of decoy hits, while 
the number of true hits (n1i) is set to the number of target hits minus n0i. These counts are then 
smoothed by averaging  over the neighboring cells. Then 𝜸(𝒙, 𝒁) = 𝒏𝟏𝒊 ∙ 𝒏𝟎,𝒕𝒐𝒕 𝒏𝟎𝒊 ∙ 𝒏𝟏,𝒕𝒐𝒕⁄  or 
𝜸(𝒙, 𝒁) = 𝟏 if n0i = 0, where n0,tot and n1,tot are the total number of decoy and target hits in all 
cells. The target and decoy PSMs are further split into non-canonical and protein-coding 
PSMs. Since there usually are not enough PSMs to estimate 𝜸(𝒙, 𝒁) for the non-canonical 
group, 𝜸(𝒙, 𝒁) is taken from all PSMs but 𝝅𝟏 𝝅𝟎⁄  is adapted for each group. Therefore, it is 
assumed that the score distributions are the same for each group, but that the ratio of true to 
wrong PSMs may change. The 𝝅𝟏 𝝅𝟎⁄  ratios are calculated for the non-canonical and protein-
coding groups separately and then the 𝝅𝟏 𝝅𝟎⁄  ratios are plugged into Equation (1). This way 
the lFDR values are calculated for every cell for both groups separately. The 𝝅𝟏 𝝅𝟎⁄  ratio in 
the non-canonical group is relatively smaller than the protein-coding 𝝅𝟏 𝝅𝟎⁄  ratio, because the 
non-canonical database is larger and mostly consists of peptides that are not present in the 
sample. This will lead to a larger non-canonical lFDR value, and to a more conservative 
filtering of non-canonical PSMs. Finally, the lFDR threshold is adjusted to allow a global FDR 
of 3% for the non-canonical and protein-coding groups. 
 
PSMs from both search tools were combined and only the intersection, meaning PSMs with 
identical Comet and Andromeda matches (same peptide sequence with the same 
modification) were retained. In order to assign peptides into source protein groups, we 
implemented a greedy bipartite graph protein grouping algorithm85. The total and ‘unique’ 
peptide counts were calculated for each protein. To calculate the adjusted peptide counts we 
sorted the proteins in each group by decreasing number of peptides and for each protein 
removed the peptides of all proteins higher up in the list. 
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To build the ipMSDB database, we searched 2,250 immunopeptidomics raw files with Comet 
(PSM FDR of 1%, as described above), and the Apache Spark cluster computing framework86 
was used to process the results and calculate the FDR. The samples were annotated with 
basic biological information for further statistical analysis.  
Ribo-Seq: Experimental Protocol 
Ribo-Seq was performed according  to Calviello et al 201687. Ribo-Seq libraries were derived 
from 80% confluent 10 cm tissue culture dishes of adherent melanoma 0D5P cells. Following 
a wash with ice-cold PBS supplemented with 100 μg/mL cycloheximide (Sigma Aldrich), the 
cells were immediately snap-frozen by placing the dishes on liquid nitrogen, which were then 
placed on wet ice. Lysis Buffer containing 20 mM Tris-Cl pH 7.4, 150 mM NaCl, 5 mM MgCl2, 
1 mM DTT (Sigma Aldrich) and 100 μg/mL cycloheximide, 1% (v/v) Triton X-100 (Calbiochem) 
and 25 U/mL TURBO DNase (Life Tech) at a volume of 400 uL was immediately added to 
frozen cells. The cells and buffer were then scraped off, mixed by pipetting and transferred to 
eppendorf tubes and kept to lyse on ice for 10 minutes. The lysate was then titurated through 
a 26-G needle for 10 times with 1 mL syringes and cleared by centrifugation for 10 min at 
20,000 x g at 4°C.  The cleared supernatant was then transferred to a pre-cooled tube on ice, 
and footprinting was performed by adding 1000U of RNase I (Life Tech. #AM2295) per 400 
μL of the lysate and incubation in a thermomixer set to 23°C, shaking at 500 rpm for 45 min. 
The digestion was stopped by adding 13 µL SUPERASE-In (Thermo, 20 U/µL) per 400 µL of 
lysate. 
Ribosomes were recovered using two MicroSpin S-400 HR columns (GE Healthcare) per 
sample. The columns were first equilibrated with a total of 3 mL of buffer containing 20 mM 
Tris-Cl pH 7.4, 150 mM NaCl, 5 mM MgCl2 and 1mM DTT by performing 6 rounds of washes 
with 500 uL of the buffer. The resin was resuspended with the last wash and drained by 
spinning for 4 min at 600 x g. One half of the sample volume was then filtered per column for 
2 min at 600 x g, and the filtered halves were then combined. To the combined flow-through, 
three volumes of Trizol LS (Life Tech) were added and RNA was extracted using the Direct-
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/758680doi: bioRxiv preprint first posted online Sep. 6, 2019; 
 
 
31 
 
zol RNA Mini-Prep kit (Zymo Research) following the manufacturer’s instructions (including 
DNase I digestion). RNA was finally eluted in 30 μL of nuclease-free water and quantified 
using the Qubit RNA Broad Range Assay (Life Tech). 
Ribosomal RNA depletion was performed from up to 5 μg of footprinted RNA using the 
RiboZero Magnetic Gold kit (Illumina) following the manufacturer’s protocol. Footprinted RNA 
was precipitated from the supernatant (90 μL) using 1.5 μL of glycoblue (Life Tech), 9μL of 3 
M sodium acetate and 300μL of ethanol by snap-freezing in liquid nitrogen and a one-hour to 
overnight incubation at -80°C and pelleted for 30 min at 21,000 x g at 4°C. The RNA pellet 
was dissolved in 10 μL of RNase-free water. 
Following rRNA depletion, isolation of short fragments and phosphorylation of these by a T4 
PNK treatment, sequencing libraries were prepared using the NEXTflex Small RNA-Seq Kit 
v3 (BiooScientific). Following the manufacturer's instructions, adapters were diluted 1:2 to 
decrease adapter dimerization. To determine the optimal number of PCR cycles for library 
amplification, a pilot PCR with the respective forward and reverse primers was performed for 
each sample for 12, 14, 16, 18 and 20 cycles. Adapter and primer sequences are published 
by BiooScientific. Products were run on a native PAGE and optimal cycle numbers were 
determined as the threshold cycle of the library product of 160 bp, which is expected size for 
ribosome protected fragments, showing up on the gel with as little adapter dimer product (130 
bp) as possible. After the final PCR, libraries were run on and excised from an agarose gel, 
followed by clean-up using Zymoclean Gel DNA Recovery (Zymo Research). Library 
quantification and validation were performed using a Qubit dsDNA HS and Bioanalyzer DNA 
HS assay, respectively. Three 0D5P control samples and three DAC treated samples (in a 
pool of 21 libraries) and additionally also two 0D5P samples (in a pool of 3 libraries) were 
sequenced on a NextSeq 500 machine at a loading concentration of 1.6pM using High Output 
Kits v2 (Illumina) with 75 cycles single-end.  
Ribo-Seq: Analysis 
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Ribo-Seq reads were stripped of adaptor sequences using cutdapt, and contaminants such 
as tRNAs and rRNA were removed by alignment to a contaminants index via Bowtie v 2.3.5, 
consisting of nucleotide sequences from known human rRNA and tRNA sequences drawn 
from the GENCODE annotation v2488. Unaligned reads from this analysis were then aligned 
to human genome version hg19 with the STAR v 2.6.1a_08-2789 splice-aware alignment tool 
allowing for up to 1 mismatch. The star genome index was built using GENCODE version 24 
(lift 37). Reads with up to 20 multi-mapping positions were included, with multi mapping reads 
beings separately treated in subsequent periodicity analysis. The RIboseQC pipeline v1.090 
was used to deduce P-site positions from Ribo-Seq reads, and this P-site data was then used 
as input to the SaTAnn pipeline v1.091 in combination with custom R scripts87 for ORF-calling. 
The SaTAnn pipeline searches for the periodic ribosomal footprint pattern characteristic of 
translated ORFs using a supplied database of transcripts, yielding a set of ORFs 
corresponding to known coding regions, as well as ORFs originating in untranslated regions, 
non-coding RNAs, intron retentions, and read-through events. 0D5P samples had a median 
of 2.8 million reads mapping to coding sequences per sample, which constituted a median of 
81% of the total reads. Since the false positive rate of periodicity based ORF calling is 
expected to be tolerant to non-periodic sources of noise such as genomic contamination, we 
included all samples for 0D5P. ORFs were called in both individual libraries and in the pooled 
set of all libraries for 0D5P, and ORFs which were fully contained within ORFs detected in 
another library were merged. ORFs were tested for periodicity, by a multitaper test87 and those 
with a p-value of below 0.05 were kept for analyses.  
Protein sequences in fasta format were generated from the coordinates of these ORFs, and 
used both for validation of peptides found using the RNA-Seq based database, and as a de 
novo assembled database for the subsequent round of peptide detection. Peptides were 
considered validated by Ribo-Seq if they matched anywhere within the translated ORF 
sequences. 
Riboseq profile plots were plotted with P-site numbers per-base on a log2 (n+1) scale. 
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10x Genomics pipeline and gene expression analyses 
For single-cell library preparation on the 10x Genomics platform, the Chromium Single Cell 3′ 
Library and SingleCell 3’ Reagent v3 were utilized, following the official user guide CG000183 
RevA, and the instrument 10x Chromium single cell controller. A total of 1,692 0D5P cells 
were captured for single-cell transcriptomics. Resulting cDNA libraries were sequenced on 
NextSeq v 2.5 (with Illumina protocol #15048776). The Cell Ranger v.3.0.1 software (10x 
Genomics) (https://support.10xgenomics.com/single-cell-gene-
expression/software/pipelines) was used to process data generated using the 10x Chromium 
platform, with a restriction to include only 1400 cells to avoid cells or debris with low UMI 
counts. This led to the detection of 19,178 genes with a mean of 125,937 mapped reads. 
Genes present in at least five cells and cells detecting at least 200 genes but no more than 
50% of mito genes were kept for the rest of the analysis. This resulted in a reduced matrix of 
15,710 genes over 1,365 cells.  
The raw counts were log-normalised using the NormalizeData implemented in the Seurat R 
package (Seurat v3). Prior to further processing, we scaled the data to remove cell-cell 
variations due to cell cycling or high percentage of mitochondrial genes. For cell cycling 
correction, we followed the scoring strategy described in Tirosh et al, 201692: each cell was 
assigned a “Cell Cycle” score and the difference between G2M and S phase scores was 
regressed out. The clustering was obtained using a graph-based method implemented in 
Seurat (FindClusters with a resolution set to 0.5) leading to the identification of 5 clusters. 
Marker genes for each cluster were identified with FindMarkers from Seurat by setting the 
logFC threshold parameter to 0.15. Marker genes with an adjusted bonferroni p-value < 0.05 
were considered significantly differentially expressed. Functional analyses were performed 
with STRING-db v11 on each cluster using their corresponding marker genes as input. 
Interrogating T-cell reactivity 
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Peptides were synthesized and lyophilized by the Protein and Peptide Chemistry Facility at 
the Ludwig Cancer Research Center (crude - >80% purity), Department of Oncology, 
University of Lausanne, or by Thermo Scientific, and resuspended in DMSO at 10 mg/mL. 
IFNγ ELISpot assays were conducted to assess the reactivity of the REP TILs towards 
antigens of interest (TAAs, noncHLAIp) using pre-coated 96-well ELISpot plates (Mabtech) 
following the manufacturer’s protocol. If necessary, REP TILs were stimulated in vitro for 14 
days with a single peptide or peptide pool at 1μg/mL before re-challenging with the peptide to 
assess IFN γ response. For this purpose, REP TILs were plated at 1-2x105 cells per well and 
challenged for 18h with cognate peptides at a final peptide concentration of 1 µM, in triplicates. 
Medium without peptide was used as negative control, and 1x Cell Stimulation Cocktail 
(eBioscience™, Thermo Fisher Scientific) was used as positive control. Spot-forming units 
were quantified using the Bioreader-6000-E automated counter (BioSys). Positive hits were 
identified by having more spots than the negative control wells, which did not contain any 
peptide, plus 3 times the standard deviation of the negative control. Positivity was confirmed 
in at least ≥ 2 independent experiments. 
Identification of circulating antigen-specific T cells in patient 0D5P was performed as 
previously described 66,93. CD19+ cells were isolated from cryopreserved PBLs using magnetic 
beads (Miltenyi) and expanded for 14 days with multimeric-CD40L (Adipogen, Epalinges, 
Switzerland, 1g/mL) and IL-4 (Miltenyi, 200 IU/mL). CD8+ T lymphocytes were isolated from 
cryopreserved PBL using magnetic beads (Miltenyi) and were co-incubated at a 1:1 ratio with 
irradiated autologous CD40-activated B cells and peptides (single peptide or pools of ≤ 50 
peptides, 1 µM each). After 12 days of in vitro expansion, CD8+ T cells were re-challenged 
with cognate peptide and T cell responses were assessed by ELISpot.   
Statistical analyses 
All statistical analyses have been indicated where appropriate. The following tools were used 
for statistical analyses:  GraphPad Prism 8, Perseus 1.5.5.3, RStudio 3.5.1 and Python 3.6. 
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HLA-binding predictions 
In order to evaluate the binding affinity of HLAIp, MixMHCpred.v2  prediction was run on all 
HLAIp of length 8-14. Peptides with a p-value < 0.05 were considered as binders.  
Sequence Specific Retention Calculator 
Sequence specific retention was calculated with an online available tool SSRCalc94: 
http://hs2.proteome.ca/SSRCalc/SSRCalcQ.html. Only unmodified peptides were included. 
Peptides and their mean retention times were plotted against the predicted hydrophobicity 
indices, which were obtained from the SSRCalc based on the 100Å C18 column, 0.1% formic 
acid separation system and without cysteine protection.  
Correlation analyses 
Correlative analyses between the immunopeptidome and transcriptome of 0D5P (Fig. 2a-d) 
were achieved by first assigning HLAp to their respective source genes. For noncHLAp, unless 
otherwise indicated, if the peptide map back to more than one non-coding source gene, the 
gene with the highest transcript expression was allocated for further analyses.  
Assessing HLAIp sampling  
For HLAIp sampling analyses, peptides were assigned to source protein groups as described 
above. Adjusted peptide counts were taken, summed over a gene, and subsequently matching 
to their corresponding expression values (either transcriptome or translatome based). 
Normalized sampling corresponds to the adjusted peptide count per protein, normalized by 
the protein length. Determination of correlation between gene expression or spectral 
coefficient of 3-periodic signal in Ribo-Seq data and HLA presentation were assessed by fitting 
a polynomial curve of degree 3 to each dataset. Pearson correlation was calculated to assess 
the correlation between the fitted curve and the data.  
Peptide position analysis 
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For peptide position analysis within a protein sequence (Supplementary Fig. 2), protein-
coding datasets fitting to the length distribution of the 95% confidence level of the lncRNA 
dataset were selected. Then, the position of HLAp, relative to the full protein sequence, was 
calculated for source lncRNA and protein-coding sequences. Since the data was not normally 
distributed, the Wilcoxon test was chosen for statistical analysis.  
PRM analyses 
For analyses of PRM statistics, MS-based intensities were taken from the initial MaxQuant 
peptide table output. Tumor-associated antigens (TAAs) for PRM and further comparative 
analyses were selected from a non-exhaustive list of known and clinically relevant TAAs.  
GTEx RNA expression analyses 
Tissue-specific gene expression data was downloaded from The Genotype-Tissue Expression 
(GTEx) project, a public resource that contains data from 53 non-diseased tissues across 
nearly 1000 individuals46. We used a custom R script to retrieve gene expression values, 
based on GTEx v7 publicly available data. In the case of multiple transcripts matching the 
same entry, expression data of the most expressed one were used. The 90th percentile 
expression of the gene in the tissue-derived tumor was reported. Investigated sample’s FPKM 
expression units were converted into TPM units for the purpose of comparison with GTEx 
data. The R-package “ComplexHeatmap”95 from the Bioconductor suite was used to draw 
heatmaps. 
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Figure Legends 
 
Fig. 1 A novel proteogenomics approach for the robust identification of noncHLAp. a A 
schematic of the entire workflow is shown, where tumor tissue samples or tumor cell lines 
were obtained from patients, and exome, RNA and Ribo-Seq performed to provide a 
framework to interrogate the non-canonical antigen repertoire. HLAp are immunoaffinity 
purified from cancer cell lines and matched tumor/healthy lung tissues and analyzed by MS. 
Immunopeptidomics spectra were then searched against RNA and Ribo-Seq based 
personalized protein sequence databases that contain non-canonical protein sequences. MS-
identified noncHLAIp were validated by targeted MS-based PRM and tested for 
immunogenicity using autologous T cells or PBMCs. b The percentage of HLA-binders with a 
MixMHCpred p-value < 0.05 is used to evaluate the accuracy of the identified HLAIp as a 
function of database size (blue line). Percentage of binders obtained for each condition is 
shown for each bar, for melanoma cell line 0D5P. c Different protein sequence databases 
combining whole exome sequencing, and inferred from RNA-Seq and Ribo-Seq data were 
utilized. NewAnce was implemented by retaining the PSM intersection of the two MS search 
tools MaxQuant and Comet, and applying group-specific FDR calculations for protHLAp and 
noncHLAp. d The percentages of protein-coding HLA-I binders were assessed for 0D5P for 
each MS search tool (MaxQuant and Comet at FDR 3%) and NewAnce. e Similar to d, the 
comparisons were performed for the different non-canonical antigen classes. f Retention 
predictions for peptides identified with melanoma 0D5P. Observed mean retention time is 
plotted against hydrophobicity indices for NewAnce identified protein coding versus non-
canonical peptides. g All peptides identified with each tool (MaxQuant, Comet, NewAnce) 
were analyzed based on their hydrophobicity indices. h MaxQuant or i Comet identified 8-14 
mer peptides were analyzed based on their HLA binding predictions which were assessed 
with MixMHCpred.  
 
Fig. 2 MS-based targeted validation by PRM and ribosome footprint pattern as evidence 
of non-canonical peptide generation. A set of protein-coding tumor-associated antigens 
and noncHLAIp (lncRNAs and TEs) from melanoma 0D5P were synthesized in its heavy 
labelled form and spiked back into replicates of eluted HLAIp from 0D5P to confirm the 
presence of the endogenous HLAIp. The proportions of confirmed and non-confirmed HLAIp 
by a PRM and b through Ribo-Seq targeted validation are shown for each of the antigen 
classes. c An example of co-elution profiles of transitions of heavy labelled and endogenous 
noncHLAIp (from lncRNA; SYLRRHLDF) from 0D5P (left) is shown. MS/MS fragmentation 
pattern further confirms the presence the endogenous peptide (Δm=10Da) (right). d, e The 
Ribo-Seq profiles for two source genes show the frequency of Ribo-Seq reads on ribosome’s 
P-site in three replicates. Library size-normalized P-sites per basepair are shown on a log2 
scale on the Y-axis, with P-sites inferred as a constant offset from the 5’ end of the footprint, 
for each read length. Colored bars represent different reading frames. Yellow bars below the 
plots represent exons. For example, the noncHLAIp SYLRRHLDF in OVOS2 (blue arrow) falls 
within two nested, Ribo-Seq-supported ORFs (red arrows), within which most P-sites (red 
bars) fall in the first reading frame.   
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Fig. 3 RNA-Seq and Ribo-Seq based gene expression analyses for the characterization 
of theprotein-coding and non-canonical HLA immunopeptidome for melanoma 0D5P. a 
Genes are ranked based on RNA expression in 0D5P. P protein-coding (orange) and non-
coding (blue) source genes, in which HLAIp were identified. The frequency distribution of gene 
expression for protein-coding and non-coding (lncRNA) genes is shown. b Magnification of 
the region of interest to show the distribution of  noncHLAIp source gene expression. c Source 
gene restricted plot. Targeted MS validation was performed and its confirmation denoted for 
all identified non-canonical and a subset of protHLAIp (selected TAAs). Confirmed hits indicate 
that one or more peptides from that source gene were validated by PRM. Point sizes represent 
the number of peptides identified per source gene. d Frequency distribution of gene 
expression for MS confirmed versus non confirmed (or inconclusive) noncHLAIp. Scatterplots 
show the correlation between e UniProt based HLA-I sampling and RNA abundance, f Ribo-
Seq-based HLA-I sampling and RNA abundance, and g Ribo-Seq-based HLA-I sampling and 
translation abundance. HLA-I sampling was calculated from adjusted peptide counts 
normalized by protein length. Determination of correlation between gene expression and HLA-
I sampling was assessed by fitting a polynomial curve of degree 3 to each dataset. Pearson 
correlations were calculated to assess the correlation between the fitted curve and the 
corresponding dataset. h With data derived from 0D5P, a comparison of the overall overlap in 
unique HLAIp identifications with RNA-Seq based and Ribo-Seq based assembled databases 
for MS search is shown. i Overlap of noncHLAIp identifications found with RNA-Seq and Ribo-
Seq based searches. j The number of identified noncHLAIp by Ribo-Seq is depicted with their 
respective source gene types.  
 
Fig. 4 ScRNA-Seq reveals non-coding transcriptional heterogeneity in melanoma 0D5P. 
a t-SNE plot of the 1,400 cells colored by their “cell cycle” scores. b Examples of genes 
that are cell-cycle dependent: ATAD2, a tumor associated antigen, and c TMEM106C, where 
a noncHLAIp originated from. d Genes of interest were plotted based on their sum normalized 
expression by scRNA-Seq and ordered based on percentage of cells that expressed the gene. 
Color codes denote the type of HLAIp identified from those genes. For clarity purposes, only 
some genes were labelled. e t-SNE plot of the 1,365 cells colored by the five identified clusters. 
Clusters were annotated based on functional enrichment analyses of marker genes. f 
Heatmap showing the scaled and centered expressions of marker genes for cluster 0. Cluster 
colors from (e) are represented above the plot. g Expression profiles of four marker genes for 
cluster 0 over all other clusters, for two well-known cancer biomarkers MITF and CTNNB1, 
and two source genes where noncHLAIp were identified: ABCB5 gene with a dORF, and 
LINC00520. The p-values represented in (b), (c) and (g) were obtained with Wilcoxon tests.  
 
Fig. 5 A comparison of non-coding source gene expression of investigated samples to 
healthy tissues (GTEx) reveals that a substantial proportion of source non-coding 
genes are tumor-specific. a The heatmap of lncRNA source genes shows the 90th percentile 
gene expression over 30 healthy tissues on the left, and on the right, the gene expression 
levels over our investigated samples. Tissue gene expression was classified into being not 
expressed (90th percentile TPM ≤ 1) in any, 1-3, or more than 3 tissues other than testis, to 
assess tumor specificity. The number of HLAIp identified per gene is depicted, as well as gene 
(GENCODE) and sample type. b The same as above is plotted also for non-coding source 
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genes identified in lung tissue samples and c specifically also for the tumor-specific 
noncHLAIp identified in lung cancer patient C3N-02289.  
 
Fig. 6 NoncHLAIp can be shared across individuals and are immunogenic. a The 
noncHLAIp-centric heatmap (left) shows the corresponding non-coding gene expression 
(90th percentile) across healthy tissues, as well as in our investigated samples (middle). The 
peptides that were MS-identified across the investigated samples, and therefore shared, are 
outlined in the rightmost heatmap. Validation by PRM was performed for multiple noncHLAIp 
across the corresponding samples and denoted with cross markings. b noncHLAIp 
identification across a large collection of immunopeptidomics datasets (ipMSDB) consisting of 
both tumor and healthy samples. Tumor specific noncHLAIp were re-identified and were 
significantly enriched in tumor samples. Tumor samples are labelled in shades of blue, * 
include tumor metastasis, myeloma, prostate, uterine, kidney, lung and pancreatic cancer, and 
neuroblastoma. Healthy samples are indicated in shades of red, # include fibroblast cells, 
monocytes, pancreatic tissue, epithelial cells, normal lung tissue, and apheresis samples. B 
and T cells mostly constitute of samples that were immortalized or rapidly expanded in culture. 
c Boxplot depicting the number of noncHLAIp identified in the different groups of samples 
derived from ipMSDB. d Reactivity was measured in melanoma 0D5P by IFNγ ELISpot using 
autologous REP TILs. Three TAAs from TYR and TYRP1, and one non-canonical dORF 
derived HLAIp from ABCB5, induced an IFNγ response. e In addition, CD8+ T lymphocytes 
from PBLs were re-challenged with autologous CD4+ blasts together with 1M of the non-
canonical  ABCB5 HLAIp. (No Ag: no peptide, positive control: 1x cell stimulation cocktail) 
 
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/758680doi: bioRxiv preprint first posted online Sep. 6, 2019; 
Patient-derived melanoma 
cell lines and lung 
tumor/healthy tissues
Exome seq RNA seq Ribosome profiling
Autologous PBMCs/TILs
Variant calling Gene expression of 
lncRNAs &  TEs
in 3 ORFs FPKM >0
Translation evidence of 
alternative ORFs
MS-based immunopeptidomics
Personalized  antigen discovery
Target validation by parallel reaction monitoring
In vitro immunogenicity of (non)-canonical 
HLA peptides
Personalized Reference 
Databases
Exome Seq RNA Seq
Exome Seq RNA Seq
Ribosomal Seq
(de novo assembly)
lncRNAs
TEs
Canonical and Non-canonical
+
+
0
50
100
150
200
8000
9000
10000
0
20
40
60
80
database size (M
B
)
lncRNAs
<1% FDR, MaxQuant
96
.8
%
75
%
83
.5
% 9
1%
88
.6
% 95
.1
% 89
.6
%
H
LA
 p
ep
tid
e 
co
un
t
predicted HLA binders 
non-binders
MaxQuant Comet
PSM 3% FDR
protein-coding and noncanonical
Search against Human Proteome 
no matches
Matched known 
proteins allowing  
mismatched I/L
no FDR
protein-coding and noncanonical
Search against Human Proteome 
no matches
protein-coding non-canonical
protein-coding
HLAp
non-canonical 
HLAp
Matched known 
proteins allowing  
mismatched I/L
PSM 3% FDRPSM 3% FDR
protein-coding non-canonical
PSM 0.001% FDR
Recalculation of local FDR based on  
protein-coding score distribution
∩∩
PSM 0.001% FDR
a
b
d
c
e
Ma
xQ
ua
nt
Co
me
t
Ne
wA
nc
e
0
5000
10000
15000
20000
H
LA
pe
pt
id
e
co
un
t 
(U
ni
pr
ot
)
Ma
xQ
ua
nt
Co
me
t
Ne
wA
nc
e
Ma
xQ
ua
nt
Co
me
t
Ne
wA
nc
e
0
200
400
600
H
LA
pe
pt
id
e
co
un
t TEs - HLA binders
lncRNAs - HLA binders
non-binders
non-binders
Uniprot - HLA binders
93
.5
 %
92
.1
%
97
.2
%
55
.4
%
74
%
83
.3
%
65
.1
%
81
% 9
7.
4%
NewAnce
NewAnce protein-coding peptides
NewAnce non-canonical peptides
Comet non-canonical peptides
MaxQuant non-canonical peptides
NewAnce non-canonical peptidesf g
h iMaxQuant non-canonical peptides Comet non-canonical peptides
Binders (p-value ≤ 0.05)
Non-binders
Binders (p-value ≤ 0.05)
Non-binders
Un
ipr
ot
 on
ly
ge
ne
ric
FP
KM
 >0
FP
KM
 >2
FP
KM
 >5
FP
KM
 >1
0
Ri
bo
-S
eq
 no
nc
0 50 100
-10
0
10
20
30
40
H
yd
ro
ph
ob
ic
ity
In
de
x
(p
re
di
ct
ed
)
Observed retention time  (min)
0 50 100
-10
0
10
20
30
40
H
yd
ro
ph
ob
ic
ity
In
de
x
(p
re
di
ct
ed
)
Observed retention time  (min)
0 50 100
-10
0
10
20
30
40
H
yd
ro
ph
ob
ic
ity
In
de
x
(p
re
di
ct
ed
)
Observed retention time  (min)
0 50 100
-10
0
10
20
30
40
H
yd
ro
ph
ob
ic
ity
In
de
x
(p
re
di
ct
ed
)
Observed retention time  (min)
Figure 1
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/758680doi: bioRxiv preprint first posted online Sep. 6, 2019; 
In
te
ns
ity
 (1
e6
)
600
400
200
0
250
150
50
0
Retention time (min)
44.0 45.0 46.0
Endogenous peptide
Heavy-labelled peptide
R
el
at
iv
e 
In
te
ns
ity
(%
)
100
0
50
100
0
50
m/z
200 400 60044.0 45.0 46.0
Retention time (min)
In
te
ns
ity
 (1
e6
)
R
el
at
iv
e 
In
te
ns
ity
(%
)
0
1
0
1
2
3
4
5
6
0D
5P
_R
01
0
1
2
3
4
5
6
0D
5P
_R
02
0
1
2
3
4
5
6
0D
5P
_R
03
56
3.8 kb
3.85 kb
3.9 kb
3.95 kb
4 kb
O
VO
S2
A
lt3
_s
ta
rt
_A
lt5
_s
to
p,
 
ne
st
ed
_O
R
F
Transcript Space
Translated noncHLAIp
Transcript Space
Translated noncHLAIp
0
2
4
6
0
2
4
6
0
2
4
6
6
6.1 kb
6.15 kb
6.2 kb
6.25 kb
6.3 kb
0D
5P
_R
03
0D
5P
_R
02
0D
5P
_R
01
R
P1
1-
72
6G
1.
1
no
ve
l t
ra
ns
cr
ip
t
m/z
250 50 75 100 250 50 75 100
TAAs
lncRNAs
MS-Targeted Validation: PRM Translation Evidence
TAAs
lncRNAs
PercentagePercentage
not confirmed
confirmed
not confirmed
confirmed
TEs 4/18TEs 15/18
71/71
60/7516/75
b
c
d
a
e
14/6551/65
30/6737/67
13/185/18
Figure 2
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/758680doi: bioRxiv preprint first posted online Sep. 6, 2019; 
h ji
uO
RF
no
ve
l
ov
erl
ap
pin
g u
OR
F
dO
RF
N-
ex
ten
sio
n
0
5
10
15
20
25
N
on
-c
an
on
ic
al
 P
ep
tid
e 
C
ou
nt
a b
c d
e f g
Datasets
lncRNA HLAIp
Protein Coding HLAIp
All lncRNA
All Protein Coding
PRM confirmation
lncRNA - Not Confirmed
lncRNA - Confirmed
−2 −1 0 1 2 3 4
0.
00
0.
01
0.
02
0.
03
0.
04
0.
05
Fitted Polynomial of degree 3
Pearson cor: 0.392
−2 −1 0 1 2 3 4
0.
00
0.
01
0.
02
0.
03
0.
04
0.
05
Fitted Polynomial of degree 3
Pearson cor: 0.431
−2 −1 0 1 2 3 4
0.
00
0.
01
0.
02
0.
03
0.
04
0.
05
Fitted Polynomial of degree 3
Pearson cor: 0.574P-Corr: .392 P-C rr: 0.431 -C rr: 0.574
Translation Rate log10 (α)RNA Abundance log10 (FPKM)RNA Abundance log10 (FPKM)
H
LA
 s
am
pl
in
g 
(s
ea
rc
he
d 
ag
ai
ns
t U
ni
pr
ot
 d
at
ab
as
e)
H
LA
 s
am
pl
in
g 
(s
ea
rc
he
d 
ag
ai
ns
t R
ib
oS
eq
 d
at
ab
as
e)
H
LA
 s
am
pl
in
g 
(s
ea
rc
he
d 
ag
ai
ns
t R
ib
oS
eq
 d
at
ab
as
e)
ov
erl
ap
pin
g d
OR
F
267119693006
Uniprot HLAIp0D5P Riboseq-based
protHLAIp
16 6156
0D5P RNA-Seq based 
noncHLAIp
0D5P Riboseq-based
noncHLAIp
Figure 3 .CC-BY-NC-ND 4.0 International licenseIt is made available under a (which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/758680doi: bioRxiv preprint first posted online Sep. 6, 2019; 
ABCB5
ATP-binding cassette sub-family B 
MITF
Melanocyte Inducing Transcription Factor
CTNNB1
catenin beta 1
LINC00520
Long intergenic 
non-protein coding RNA 520 
da
b
c
p = 3.4e-59
p = 3e-118
p = 1e-06
p = 2.9e-76
p = 1e−36
p = 2e-21
ATAD2
ATPase family AAA domain-containing protein 2
TMEM106C
transmembrane protein 106C
f
g
e p = 2e−30
0.0
0.5
1.0
1.5
N
or
m
al
iz
ed
 E
xp
re
ss
io
n p = 3e−18
0
1
2
3
p = 1.2e−34
0
1
2
3
p = 1.8e−06
0
1
2
N
or
m
al
iz
ed
 E
xp
re
ss
io
n
N
or
m
al
iz
ed
 E
xp
re
ss
io
n
N
or
m
al
iz
ed
 E
xp
re
ss
io
n
Cluster 0 other Cluster 0 other
Cluster 0 other Cluster 0 other
0.0
0.5
1.0
1.5
2.0
N
or
m
al
iz
ed
 E
xp
re
ss
io
n
0.0
0.5
1.0
1.5
2.0
N
or
m
al
iz
ed
 E
xp
re
ss
io
n
G1 G2M S
G1 G2M S
−2 −1 0 1 2
Value
0
10
00
20
00
30
00
40
00
C
ou
nt
ZMAT3
ZFYVE16
ZFAND5
WSB1
UGCG
UBAP1L
TTYH3
TRIB2
STXBP1
ST3GAL6
SLCO5A1
SLC38A8
SERPINE2
SEMA6A
SELENOW
SCD
SAT1
S100A6
RPL9
RPL7A
RPL6
RPL41
RPL39
RPL37
RPL36
RPL35A
RPL35
RPL34
RPL32
RPL29
RPL27
RPL26
RPL24
RPL15
RPL12
RPL11
RAB17
PSAP
PRUNE2
PLXNC1
PHPT1
NPDC1
NORAD
NEAT1
MYO5A
MITF
MGMT
MALAT1
LINC00520
LAMB2
HIPK2
GPR161
FTL
FBXW5
FAM210B
EIF4B
EEF2
DAB2
CTSL
CTNNB1
CHPF
CHMP1B
CERK
C9orf16
C11orf96
BBC3
ATP6V1G1
AL162457.2
ABHD2
ABCB5
−40
−20
0
20
−30 −20 −10 0 10 20
tSNE_1
tS
N
E
_2
G1
G2M
S
−40
−20
0
20
−30 −20 −10 0 10 20
tSNE_1
tS
N
E
_2
0 - Ribosome, translation initiation
1 - Melanin biosynthesis
2 - Cell Cycle
3 - DNA replication, mismatch repair
4 - Proteasome,
 Oxidative Phosphorylation
B2M
HLA−C
HLA−B
HLA−A
ST3GAL5
ARAP1
TMEM168
CSK
JOSD2
EEF1B2
USP53
SLCO5A1
ZNF720
FAM81A
AC083862.2
MAPK6 CNRIP1
LBX2−AS1
SLC24A1
CREB3
TPST2
TRIM2
CYBC1
RGS20
ATOH8
PPP6R2
ZMYM4
SEMA6D
ERCC8
FBXL4
ZNF280D
ZNF146
ARMCX4
FASTKD1
ABCB5
SMIM12
AC093635.1
IKZF5 LINC00681
ZNF788P
PPCDC
MOK
FAM149A
LCP2
TEX41
RTL8A
AKR1A1 CHCHD6
WARS
TMEM106C
SLC7A1
PMS1
CCNC
SLC22A18
SOCS2
PCIF1
IGSF11
CCDC110
DCTGPR143
SOX10
PMEL
MAGEA6
CPSF1
FAP
TYR
PAX3
ATAD2
TYRP1
PRAME
RAB30−AS1
MCPH1−AS1
RP11−259K5.2
LINC00520
FAM225A
CTD−2630F21.1
LINC01198
NNT−AS1
LINC01588
RP11−440D17.3
RP11−147L13.15
AGAP2−AS1
RP11−11N9.4
UBA6−AS1
RP11−164J13.1
SNHG18
LINC01010
ZBED5−AS1
CTD−2380F24.1
RP1−206D15.6
TTN−AS1
DHRS4−AS1
RP11−983P16.4
RP11−277P12.20
RP11−529E10.7
RP11−223C24.1
RP11−486G15.2
RP11−452F19.3
LINC01116
OTUD6B−AS1
ATP6V0E2−AS1
RP11−615I2.2
LINC01272
RP11−390P2.4
CTD−2336O2.1
0
25
50
75
100
0 2000 4000
Normalized Expression (sum)
%
  E
xp
re
ss
in
g 
C
el
ls
●
●
●
●
TAAs- RNA- and Ribo-Seq
HLA
nonc- RNA-Seq
1000 random genes
● nonc- Ribo-Seq
● nonc- RNA- and Ribo-Seq
Figure 4
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/758680doi: bioRxiv preprint first posted online Sep. 6, 2019; 
GTEx 90th Percentile RNA Expression
ln
cR
N
A
 G
en
es
Ad
ip
os
e.
Ti
ss
ue
Ad
re
na
l.G
la
nd
Bl
ad
de
r
Bl
oo
d
Bl
oo
d.
Ve
ss
el
Br
ai
n
Br
ea
st
Ce
rv
ix.
Ut
er
i
Co
lo
n
Es
op
ha
gu
s
Fa
llo
pi
an
.T
ub
e
He
ar
t
Ki
dn
ey
Li
ve
r
Lu
ng
M
us
cle
Ne
rv
e
O
va
ry
Pa
nc
re
as
Pi
tu
ita
ry
Pr
os
ta
te
Sa
liv
ar
y.
G
la
nd
Sk
in
Sm
al
l.I
nt
es
tin
e
Sp
le
en
St
om
ac
h
Te
st
is
Th
yr
oi
d
Ut
er
us
Va
gi
na
Ti
ss
ue
 E
xp
re
ss
io
n
Ty
pe
#P
ep
tid
es
Investigated
Samples
RNA Expression
0D
5P
0M
M
74
5
0N
VC
M
e2
90
T1
01
5A
T1
18
5B
M
e2
75
Gtex Expression
[log10(TPM+1)]
0
2
4
6
8
Tissue Expression
> 3 tissues
3 tissues
2 tissues
1 tissue
Not Expressed
Type
lncRNA
pseudogene
#Peptides
4
3
2
1
Samples Expression
[log10(TPM+1)]
0
2
4
6
8
Melanoma
GTEx 90th Percentile RNA Expression
ln
cR
N
A
 G
en
es
C
3N
−0
26
71
_t
um
or
C
3N
−0
22
89
_t
um
or
C
3N
−0
26
71
_n
or
m
al
C
3N
−0
22
89
_n
or
m
al Type
lncRNA
pseudogene
#Peptides
3
2
1
GTEx 90th Percentile RNA Expression
ln
cR
N
A
 G
en
es
RP11-566H8.3 
MTCYBP18
HAGLROS
HAGLROS
LINC00649
RP11-398K22.12
TMEM254−AS1
ZNF271P
MIR205HG
NSUN5P1
Ad
ip
os
e.
Ti
ss
ue
Ad
re
na
l.G
la
nd
Bl
ad
de
r
Bl
oo
d
Bl
oo
d.
Ve
ss
el
Br
ai
n
Br
ea
st
Ce
rv
ix.
Ut
er
i
Co
lo
n
Es
op
ha
gu
s
Fa
llo
pi
an
.T
ub
e
He
ar
t
Ki
dn
ey
Li
ve
r
Lu
ng
M
us
cle
Ne
rv
e
O
va
ry
Pa
nc
re
as
Pi
tu
ita
ry
Pr
os
ta
te
Sa
liv
ar
y.
G
la
nd
Sk
in
Sm
al
l.I
nt
es
tin
e
Sp
le
en
St
om
ac
h
Te
st
is
Th
yr
oi
d
Ut
er
us
Va
gi
na
Tis
su
e E
xp
re
ss
ion
STYITKNFK
KINPLIKLI
KVLAGTVLFK
VLAGTVLFK
KFSLAPVSL
ILSSHATTRK
KAASKATPK
RLHSGPVTK
SVMAHTVGPR
AVISSAGLLSAK
C
3N
−0
22
89
_t
um
or
C
3N
−0
22
89
_n
or
m
al
Gtex Expression
[log10(TPM+1)]
0
2
4
6
8
Tissue Expression
Samples Expression
[log10(TPM+1)]
0
2
4
6
8
Sample_type
Tumor lung tissue
Healthy lung tissue
HL
A 
Pe
pt
ide
a
b c
Sa
mp
le 
Ex
pr
es
sio
n
Ti
ss
ue
 E
xp
re
ss
io
n
#P
ep
tid
es Investigated
Samples
RNA ExpressionTy
pe
Ad
ip
os
e.
Ti
ss
ue
Ad
re
na
l.G
la
nd
Bl
ad
de
r
Bl
oo
d
Bl
oo
d.
Ve
ss
el
Br
ai
n
Br
ea
st
Ce
rv
ix.
Ut
er
i
Co
lo
n
Es
op
ha
gu
s
Fa
llo
pi
an
.T
ub
e
He
ar
t
Ki
dn
ey
Li
ve
r
Lu
ng
M
us
cle
Ne
rv
e
O
va
ry
Pa
nc
re
as
Pi
tu
ita
ry
Pr
os
ta
te
Sa
liv
ar
y.
G
la
nd
Sk
in
Sm
al
l.I
nt
es
tin
e
Sp
le
en
St
om
ac
h
Te
st
is
Th
yr
oi
d
Ut
er
us
Va
gi
na
> 3 tissues
3 tissues
2 tissues
1 tissue
Not Expressed
Figure 5
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/758680doi: bioRxiv preprint first posted online Sep. 6, 2019; 
GTEx 90th Percentile RNA Expression
AAFDRAVHF
GSDFGGGGSY
DVDIHKDLY
SVASISLTK
VTDQASHIY
YTDEQNSSTTY
YLATDHQKQLL
KSDLSKPLSY
PAALQKDVSL
DPGLGVLRKTAL
APKSSSGFSL
IFLKKHFLF
ATEHDKNSTNIY
YLDPAQQNL
YLDPAQQNLY
MTDRHAGTY
VVTKVNKEV
MVAESPPRV
EVAPGALGTR
VAAAESHPL
MLAEIHPKAGL
MLAEIHPKA
MTMSTILSKK
RQTGLSRLY
ETDIEMETRY
KTFDKDFFM
VSDEWENLKY
Ad
ip
os
e.
Ti
ss
ue
Ad
re
na
l.G
la
nd
Bl
ad
de
r
Bl
oo
d
Bl
oo
d.
Ve
ss
el
Br
ai
n
Br
ea
st
C
er
vi
x.
U
te
ri
C
ol
on
Es
op
ha
gu
s
Fa
llo
pi
an
.T
ub
e
H
ea
rt
Ki
dn
ey
Li
ve
r
Lu
ng
M
us
cl
e
N
er
ve
O
va
ry
Pa
nc
re
as
Pi
tu
ita
ry
Pr
os
ta
te
Sa
liv
ar
y.
G
la
nd
Sk
in
Sm
al
l.I
nt
es
tin
e
Sp
le
en
St
om
ac
h
Te
st
is
Th
yr
oi
d
U
te
ru
s
Va
gi
na
Investigated Samples
RNA Expression
0D
5P
0M
M
74
5
0N
VC
M
e2
90
T1
01
5A
T1
18
5B
M
e2
75
C
3N
−0
26
71
_t
um
or
C
3N
−0
22
89
_t
um
or
C
3N
−0
26
71
_n
or
m
al
C
3N
−0
22
89
_n
or
m
al
Investigated Samples
MS detection
0D
5P
0M
M
74
5
0N
VC
M
e2
90
T1
01
5A
T1
18
5B
M
e2
75
C
3N
−0
26
71
_t
um
or
C
3N
−0
22
89
_t
um
or
C
3N
−0
26
71
_n
or
m
al
C
3N
−0
22
89
_n
or
m
al
Gtex Expression
[log10(TPM+1)]
0
2
4
6
8
Samples Expression
[log10(TPM+1)]
0
2
4
6
8
Peptide MS detection
Present
Absent
PRM tested and not 
confirmed
Sample type
Melanoma
Tumor lung tissue
Healthy lung tissue
PRM confirmed
a
no
nc
H
LA
Ip
KYKDRTNILFno Ag
d
e
KVKPEGASL
KLEAGLLGR
FSDFQTQVLSNY
MSAKPSWTY
DAAQSELARFHR
RVRPFSEGSTETY
DSFFGETSR
ETIQNTHSF
FSSSVAVTDK
KSDLSKPLSY
MVWEGHPRER
FVSHTYNYKR
EVYSGSTHF
APKLMVRPF
STANLSTAR
NTAIATFLQRK
VFDVGKGNM
HASFSTSSL
VTDQASHIY
FSDSGSGTDY
EISNVNWVSR
YLATDHQKQLL
THDVNDFVL
DAGPADAAGR
AVTDQASHIY
EAQDPGSAAAGR
KELFLERIL
RMAKEPRTY
KMIGQNHSH
STMPSPIDHPR
MPSPIDHPR
ETILANMVKSR
QTEKENSKY
HTCNHSTLGGQGR
MTYQETFTQHRY
KMEETTVTY
ILYQNPKTLKF
ETISPRPSI
GQTASSAHF
SSSFIILSK
KQWIGFMTY
STETPHSGVKY
KPIFLTQSL
TPNSLAKPL
HVFSSESPRR
VMKGINQGY
HVCSQLPAEK
THLEDPHLM
SVASISLTK
PAALQKDVSL
EAVHSKNILILR
HTTSVMENK
MTVQPPELAR
MGGFVSHTY
VFLKFSRRF
EVSHPNMSGR
DVKDGKYSQA
EAFSKQWQGR
HPKATVVTPM
HAAGALPGTGR
HSSDSSLHLR
FLYNQTNIRM
HVFSSESPR
NTDSPLHFVD
ISASQSTGITGV
TEIEAIHF
TAYWSNVQK
EVQNQGASR
RVSHLTSSV
QTELSQLLK
GGSFGGGGSY
TSFSTLPTVTK
KEFAFLEHSL
RQVMKGINQGY
HTSSDQWKK
EHSVENGSI
HSSPVSRHY
DVDIHKDLY
GSDFGGGGSY
MTLRPTQPR
MVFDVGKGNMYF
AETSPADSL
TSASSISILR
AGRPLLLSKGSLM
EVPGATKLLAAR
VFIKNIRAKF
MVWEGHPRERR
YTDEQNSSTTY
TEVAEVGESL
DTVWITMRK
RQQQIQHLR
Sample HLAIp Count
970 8870 41020
Samples
Tu
m
or
-s
pe
ci
fic
 n
on
cH
LA
Ip
Tumor samples Healthy samplesb
Me
lan
om
a
Me
nin
gio
ma
Le
uk
em
ia
Liv
er
 C
an
ce
r
Co
lon
 C
an
ce
r
Ov
ar
ian
 C
an
ce
r
Br
ain
 C
an
ce
r
Ot
he
r *
B 
ce
lls
T c
ell
s
de
nd
rit
ic 
ce
lls
liv
er
Ot
he
r #
c
B &
 T c
ells
0.
00
00
0.
00
02
0.
00
04
0.
00
06
0.
00
08
0.
00
10
0.
00
12
no
nc
/p
ro
t H
LA
Ip
 C
ou
nt
can
cer
 inc
l.
me
lan
om
a
hea
lthy
 inc
l.
B &
 T c
ellshea
lthy
 w/o
B &
 T c
ellsme
lan
om
a 
0D5P CD8+ (PBL) IVS 
TAAsnoncHLAIp
0D5P REP TILs
γ
γ
IF
N
sp
ot
s/
10
6
C
D
8+
(P
BL
)
IF
N
sp
ot
s/
10
6
TI
Ls
no
Ag
KY
KD
RT
NI
LF
HY
YV
SM
DA
L
RY
NA
DI
ST
F
RL
PS
SA
DV
EF
po
sit
ive
co
ntr
ol
0
200
400
600
1000
1500
2000
700000
800000
No
Ag
KY
KD
RT
NI
LF
po
sit
ive
co
ntr
ol
0
500
1000
1500
700000
800000
900000
Figure 6
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/758680doi: bioRxiv preprint first posted online Sep. 6, 2019; 
